{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:11:39Z","timestamp":1793398299118,"version":"4.5.0"},"reference-count":345,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20240484526"],"award-info":[{"award-number":["20240484526"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tuberculosis (TB) remains a prominent global health challenge, with the World Health Organization documenting over 1 million annual fatalities. Despite the deployment of the Bacille Calmette-Gu\u00e9rin (BCG) vaccine and available therapeutic agents, the escalation of drug-resistant\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    strains underscores the pressing need for more efficacious vaccines and treatments. This review meticulously maps out the contemporary landscape of TB vaccine development, with a focus on antigen identification, clinical trial progress, and the obstacles and future trajectories in vaccine research. We spotlight innovative approaches, such as multi-antigen vaccines and mRNA technology platforms. Furthermore, the review delves into current TB therapeutics, particularly for multidrug-resistant tuberculosis (MDR-TB), exploring promising agents like bedaquiline (BDQ) and delamanid (DLM), as well as the potential of host-directed therapies. The hurdles in TB vaccine and therapeutic development encompass overcoming antigen diversity, enhancing vaccine effectiveness across diverse populations, and advancing novel vaccine platforms. Future initiatives emphasize combinatorial strategies, the development of anti-TB compounds targeting novel pathways, and personalized medicine for TB treatment and prevention. Despite notable advances, persistent challenges such as diagnostic failures and protracted treatment regimens continue to impede progress. This work aims to steer future research endeavors toward groundbreaking TB vaccines and therapeutic agents, providing crucial insights for enhancing TB prevention and treatment strategies.\n                  <\/jats:p>","DOI":"10.1186\/s43556-024-00243-6","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:38:54Z","timestamp":1737502734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Tuberculosis vaccines and therapeutic drug: challenges and future directions"],"prefix":"10.1186","volume":"6","author":[{"given":"Yajing","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizi","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Parkkila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Aspatwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0333-890X","authenticated-orcid":false,"given":"Wenping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"1590","key":"243_CR1","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1098\/rstb.2011.0316","volume":"367","author":"S Gagneux","year":"2012","unstructured":"Gagneux S. Host-pathogen coevolution in human tuberculosis. Philos Trans R Soc Lond B Biol Sci. 2012;367(1590):850\u20139. https:\/\/doi.org\/10.1098\/rstb.2011.0316.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1","key":"243_CR2","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1002\/mco2.419","volume":"5","author":"L Zhuang","year":"2024","unstructured":"Zhuang L, Yang L, Li L, Ye Z, Gong W. Mycobacterium tuberculosis: immune response, biomarkers, and therapeutic intervention. MedComm. 2024;5(1):e419. https:\/\/doi.org\/10.1002\/mco2.419.","journal-title":"MedComm"},{"issue":"2","key":"243_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/med4.58","volume":"2","author":"L Yang","year":"2024","unstructured":"Yang L, Ye Z, Li L, Zhuang L, Guan J, Gong W. Visualization analysis of research progress and trends in coexistence of lung cancer and pulmonary tuberculosis using bibliometrics. Med Adv. 2024;2(2):144\u201364. https:\/\/doi.org\/10.1002\/med4.58.","journal-title":"Med Adv"},{"issue":"8","key":"243_CR4","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/vaccines11081304","volume":"11","author":"L Zhuang","year":"2023","unstructured":"Zhuang L, Ye Z, Li L, Yang L, Gong W. Next-Generation TB Vaccines: Progress, Challenges, and Prospects. Vaccines (Basel). 2023;11(8):1304. https:\/\/doi.org\/10.3390\/vaccines11081304.","journal-title":"Vaccines (Basel)"},{"key":"243_CR5","unstructured":"WHO. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. p. 1-75."},{"key":"243_CR6","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1016\/j.csbj.2021.07.035","volume":"19","author":"E Broset","year":"2021","unstructured":"Broset E, Calvet Seral J, Arnal C, Uranga S, Kanno AI, Leite LCC, et al. Engineering a new vaccine platform for heterologous antigen delivery in live-attenuated Mycobacterium tuberculosis. Comput Struct Biotechnol J. 2021;19:4273\u201383. https:\/\/doi.org\/10.1016\/j.csbj.2021.07.035.","journal-title":"Comput Struct Biotechnol J"},{"key":"243_CR7","doi-asserted-by":"publisher","unstructured":"Zhuang L, Ye Z, Li L, Yang L, Gong W. Next-generation TB vaccines: progress, challenges, and prospects. Vaccines (Basel). 2023;11(8). https:\/\/doi.org\/10.3390\/vaccines11081304.","DOI":"10.3390\/vaccines11081304"},{"issue":"12","key":"243_CR8","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1080\/21645515.2021.1977057","volume":"17","author":"V Kayser","year":"2021","unstructured":"Kayser V, Ramzan I. Vaccines and vaccination: history and emerging issues. Hum Vaccin Immunother. 2021;17(12):5255\u201368. https:\/\/doi.org\/10.1080\/21645515.2021.1977057.","journal-title":"Hum Vaccin Immunother"},{"key":"243_CR9","doi-asserted-by":"publisher","first-page":"750124","DOI":"10.3389\/fmicb.2021.750124","volume":"12","author":"SHE Kaufmann","year":"2021","unstructured":"Kaufmann SHE. Vaccine development against tuberculosis over the last 140 years: failure as part of success. Front Microbiol. 2021;12:750124. https:\/\/doi.org\/10.3389\/fmicb.2021.750124.","journal-title":"Front Microbiol"},{"key":"243_CR10","doi-asserted-by":"publisher","unstructured":"Wang J, Mi J, Liang Y, Wu X, Zhang J, Liu Y et al. RNA-seq Analysis of the BCG Vaccine in a Humanized Mouse Model. Zoonoses. 2023;3(1):1\u201310. https:\/\/doi.org\/10.15212\/zoonoses-2022-0035.","DOI":"10.15212\/zoonoses-2022-0035"},{"issue":"3","key":"243_CR11","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1002\/ctd2.301","volume":"4","author":"W Gong","year":"2024","unstructured":"Gong W, Du J, Aspatwar A, Zhuang L, Zhao Y. Revisiting Bacille Calmette-Gu\u00e9rin revaccination strategies: timing of immunization, Mycobacterium tuberculosis and non-tuberculous mycobacteria infections, strain potency and standardization of randomized controlled trials. Clin Transl Discov. 2024;4(3):e301. https:\/\/doi.org\/10.1002\/ctd2.301.","journal-title":"Clin Transl Discov"},{"issue":"3","key":"243_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S1473-3099(23)00514-5","volume":"24","author":"W Gong","year":"2024","unstructured":"Gong W, Du J. Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control. Lancet Infect Dis. 2024;24(3):224\u20136. https:\/\/doi.org\/10.1016\/S1473-3099(23)00514-5.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"243_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/jpm13030408","volume":"13","author":"F Jiang","year":"2023","unstructured":"Jiang F, Sun T, Cheng P, Wang J, Gong W. A summary on tuberculosis vaccine development\u2014where to go? J Pers Med. 2023;13(3):408. https:\/\/doi.org\/10.3390\/jpm13030408.","journal-title":"J Pers Med"},{"key":"243_CR14","doi-asserted-by":"publisher","first-page":"117594","DOI":"10.1016\/j.lfs.2020.117594","volume":"252","author":"S Fatima","year":"2020","unstructured":"Fatima S, Kumari A, Das G, Dwivedi VP. Tuberculosis vaccine: a journey from BCG to present. Life Sci. 2020;252:117594. https:\/\/doi.org\/10.1016\/j.lfs.2020.117594.","journal-title":"Life Sci"},{"issue":"9","key":"243_CR15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","volume":"271","author":"GA Colditz","year":"1994","unstructured":"Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis meta-analysis of the published literature. JAMA. 1994;271(9):698\u2013702.","journal-title":"JAMA"},{"issue":"8986","key":"243_CR16","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/s0140-6736(95)92348-9","volume":"346","author":"PE Fine","year":"1995","unstructured":"Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346(8986):1339\u201345. https:\/\/doi.org\/10.1016\/s0140-6736(95)92348-9.","journal-title":"Lancet"},{"key":"243_CR17","doi-asserted-by":"publisher","unstructured":"Singh AK, Netea MG, Bishai WR. BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases. J Clin Invest. 2021;131(11). https:\/\/doi.org\/10.1172\/jci148291.","DOI":"10.1172\/jci148291"},{"key":"243_CR18","doi-asserted-by":"publisher","first-page":"830497","DOI":"10.3389\/fimmu.2022.830497","volume":"13","author":"W Gong","year":"2022","unstructured":"Gong W, Pan C, Cheng P, Wang J, Zhao G, Wu X. Peptide-based vaccines for tuberculosis. Front Immunol. 2022;13:830497. https:\/\/doi.org\/10.3389\/fimmu.2022.830497.","journal-title":"Front Immunol"},{"issue":"1","key":"243_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s43556-024-00177-z","volume":"5","author":"J Wang","year":"2024","unstructured":"Wang J, Jiang F, Cheng P, Ye Z, Li L, Yang L, et al. Construction of novel multi-epitope-based diagnostic biomarker HP16118P and its application in the differential diagnosis of Mycobacterium tuberculosis latent infection. Mol Biomed. 2024;5(1):15. https:\/\/doi.org\/10.1186\/s43556-024-00177-z.","journal-title":"Mol Biomed"},{"issue":"1","key":"243_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/id9.0000000000000104","volume":"4","author":"C Peng","year":"2024","unstructured":"Peng C, Jiang F, Liu Y, Xue Y, Cheng P, Wang J, et al. Development and evaluation of a promising biomarker for diagnosis of latent and active tuberculosis infection. Infect Dis Immun. 2024;4(1):10\u201324. https:\/\/doi.org\/10.1097\/id9.0000000000000104.","journal-title":"Infect Dis Immun"},{"issue":"4","key":"243_CR21","doi-asserted-by":"publisher","first-page":"e0143822","DOI":"10.1128\/spectrum.01438-22","volume":"10","author":"W Gong","year":"2022","unstructured":"Gong W, Liang Y, Wang J, Liu Y, Xue Y, Mi J, et al. Prediction of Th1 and cytotoxic T lymphocyte epitopes of Mycobacterium tuberculosis and evaluation of their potential in the diagnosis of tuberculosis in a mouse model and in humans. Microbiol Spectr. 2022;10(4):e0143822. https:\/\/doi.org\/10.1128\/spectrum.01438-22.","journal-title":"Microbiol Spectr"},{"issue":"1393","key":"243_CR22","doi-asserted-by":"publisher","first-page":"666290","DOI":"10.3389\/fimmu.2021.666290","volume":"12","author":"W Gong","year":"2021","unstructured":"Gong W, Liang Y, Mi J, Jia Z, Xue Y, Wang J, et al. Peptides-based vaccine MP3RT induced protective immunity against mycobacterium tuberculosis infection in a humanized mouse model. Front Immunol. 2021;12(1393):666290. https:\/\/doi.org\/10.3389\/fimmu.2021.666290.","journal-title":"Front Immunol"},{"key":"243_CR23","unstructured":"WHO. WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis \u2013 rapid diagnostics for tuberculosis detection. Geneva: World Health Organization; 2024. p. 1-160. https:\/\/www.who.int\/publications\/i\/item\/9789240089488."},{"key":"243_CR24","unstructured":"WHO. Global tuberculosis report 2024. Geneva: World Health Organization; 2024. p. 1-68."},{"key":"243_CR25","unstructured":"WHO. WHO consolidated guidelines on tuberculosis, Module 4: Treatment \u2013 drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022. p. 1-72. https:\/\/www.who.int\/publications\/i\/item\/9789240048126."},{"issue":"3","key":"243_CR26","doi-asserted-by":"publisher","first-page":"100129","DOI":"10.1016\/j.imj.2024.100129","volume":"3","author":"D Liu","year":"2024","unstructured":"Liu D, Zhao B, Zheng Y, Ou X, Wang S, Zhou Y, et al. Characterization of isoniazid resistance and genetic mutations in isoniazid-resistant and rifampicin-susceptible Mycobacterium tuberculosis in China. Infect Med (Beijing). 2024;3(3):100129. https:\/\/doi.org\/10.1016\/j.imj.2024.100129.","journal-title":"Infect Med (Beijing)"},{"key":"243_CR27","doi-asserted-by":"publisher","first-page":"116785","DOI":"10.1016\/j.ejmech.2024.116785","volume":"277","author":"X Wei","year":"2024","unstructured":"Wei X, Yue L, Zhao B, Jiang N, Lei H, Zhai X. Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment. Eur J Med Chem. 2024;277:116785. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116785.","journal-title":"Eur J Med Chem"},{"issue":"11","key":"243_CR28","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00228-024-03749-8","volume":"80","author":"M Sarkar","year":"2024","unstructured":"Sarkar M, Sarkar J. Therapeutic drug monitoring in tuberculosis. Eur J Clin Pharmacol. 2024;80(11):1659\u201384. https:\/\/doi.org\/10.1007\/s00228-024-03749-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"243_CR29","doi-asserted-by":"publisher","first-page":"100163","DOI":"10.1016\/j.cellin.2024.100163","volume":"3","author":"Y Yang","year":"2024","unstructured":"Yang Y, Chen YZ, Xia T. Optimizing antigen selection for the development of tuberculosis vaccines. Cell Insight. 2024;3(3):100163. https:\/\/doi.org\/10.1016\/j.cellin.2024.100163.","journal-title":"Cell Insight"},{"issue":"1","key":"243_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-2249.2004.02593.x","volume":"138","author":"B Hamasur","year":"2004","unstructured":"Hamasur B, Haile M, Pawlowski A, Schroder U, Kallenius G, Svenson SB. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab\u2019) fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol. 2004;138(1):30\u20138. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02593.x.","journal-title":"Clin Exp Immunol"},{"issue":"26","key":"243_CR31","doi-asserted-by":"publisher","first-page":"15688","DOI":"10.1073\/pnas.95.26.15688","volume":"95","author":"R Teitelbaum","year":"1998","unstructured":"Teitelbaum R, Glatman-Freedman A, Chen B, Robbins JB, Unanue E, Casadevall A, et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci USA. 1998;95(26):15688\u201393. https:\/\/doi.org\/10.1073\/pnas.95.26.15688.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"243_CR32","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41467-021-20930-0","volume":"12","author":"A Watson","year":"2021","unstructured":"Watson A, Li H, Ma B, Weiss R, Bendayan D, Abramovitz L, et al. Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis. Nat Commun. 2021;12(1):602. https:\/\/doi.org\/10.1038\/s41467-021-20930-0.","journal-title":"Nat Commun"},{"issue":"1","key":"243_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41541-023-00710-1","volume":"8","author":"S Krishnananthasivam","year":"2023","unstructured":"Krishnananthasivam S, Li H, Bouzeyen R, Shunmuganathan B, Purushotorman K, Liao X, et al. An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis. NPJ vaccines. 2023;8(1):127. https:\/\/doi.org\/10.1038\/s41541-023-00710-1.","journal-title":"NPJ vaccines"},{"key":"243_CR34","doi-asserted-by":"publisher","first-page":"1238586","DOI":"10.3389\/fimmu.2023.1238586","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Xu JC, Hu ZD, Fan XY. Advances in protein subunit vaccines against tuberculosis. Front Immunol. 2023;14:1238586. https:\/\/doi.org\/10.3389\/fimmu.2023.1238586.","journal-title":"Front Immunol"},{"key":"243_CR35","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.3389\/fimmu.2019.01968","volume":"10","author":"M Correia-Neves","year":"2019","unstructured":"Correia-Neves M, Sundling C, Cooper A, K\u00e4llenius G. Lipoarabinomannan in active and passive protection against tuberculosis. Front Immunol. 2019;10:1968. https:\/\/doi.org\/10.3389\/fimmu.2019.01968.","journal-title":"Front Immunol"},{"issue":"14","key":"243_CR36","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1111\/febs.16369","volume":"289","author":"R Pal","year":"2022","unstructured":"Pal R, Bisht MK, Mukhopadhyay S. Secretory proteins of Mycobacterium tuberculosis and their roles in modulation of host immune responses: focus on therapeutic targets. FEBS J. 2022;289(14):4146\u201371. https:\/\/doi.org\/10.1111\/febs.16369.","journal-title":"FEBS J"},{"issue":"4","key":"243_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.tube.2013.03.003","volume":"93","author":"A Bekmurzayeva","year":"2013","unstructured":"Bekmurzayeva A, Sypabekova M, Kanayeva D. Tuberculosis diagnosis using immunodominant, secreted antigens of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2013;93(4):381\u20138. https:\/\/doi.org\/10.1016\/j.tube.2013.03.003.","journal-title":"Tuberculosis (Edinb)"},{"issue":"4","key":"243_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2217\/fmb.12.14","volume":"7","author":"C Boon","year":"2012","unstructured":"Boon C, Dick T. How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later. Future Microbiol. 2012;7(4):513\u20138. https:\/\/doi.org\/10.2217\/fmb.12.14.","journal-title":"Future Microbiol"},{"key":"243_CR39","doi-asserted-by":"publisher","first-page":"105068","DOI":"10.1016\/j.micpath.2021.105068","volume":"158","author":"A Verma","year":"2021","unstructured":"Verma A, Radotra BD, Sharma S. Role of resuscitation promoting factors in reactivation of latent tuberculosis during high glucose conditions employing human granuloma in vitro model. Microb Pathog. 2021;158:105068. https:\/\/doi.org\/10.1016\/j.micpath.2021.105068.","journal-title":"Microb Pathog"},{"issue":"1","key":"243_CR40","doi-asserted-by":"publisher","first-page":"19700","DOI":"10.1038\/s41598-021-99257-1","volume":"11","author":"A Verma","year":"2021","unstructured":"Verma A, Kaur M, Singh LV, Aggarwal D, Verma I, Radotra BD, et al. Reactivation of latent tuberculosis through modulation of resuscitation promoting factors by diabetes. Sci Rep. 2021;11(1):19700. https:\/\/doi.org\/10.1038\/s41598-021-99257-1.","journal-title":"Sci Rep"},{"issue":"3","key":"243_CR41","doi-asserted-by":"publisher","first-page":"116472","DOI":"10.1016\/j.diagmicrobio.2024.116472","volume":"110","author":"H Qureshi","year":"2024","unstructured":"Qureshi H, Shah Z, Raja MAZ, Alshahrani MY, Khan WA, Shoaib M. Machine learning investigation of tuberculosis with medicine immunity impact. Diagn Microbiol Infect Dis. 2024;110(3):116472. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2024.116472.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"243_CR42","doi-asserted-by":"publisher","first-page":"106998","DOI":"10.1016\/j.mimet.2024.106998","volume":"224","author":"DB Olawade","year":"2024","unstructured":"Olawade DB, Teke J, Fapohunda O, Weerasinghe K, Usman SO, Ige AO, et al. Leveraging artificial intelligence in vaccine development: a narrative review. J Microbiol Methods. 2024;224:106998. https:\/\/doi.org\/10.1016\/j.mimet.2024.106998.","journal-title":"J Microbiol Methods"},{"issue":"1","key":"243_CR43","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/jpm13010116","volume":"13","author":"C Peng","year":"2023","unstructured":"Peng C, Tang F, Wang J, Cheng P, Wang L, Gong W. Immunoinformatic-Based Multi-Epitope Vaccine Design for Co-Infection of Mycobacterium tuberculosis and SARS-CoV-2. J Pers Med. 2023;13(1):116. https:\/\/doi.org\/10.3390\/jpm13010116.","journal-title":"J Pers Med"},{"issue":"4","key":"243_CR44","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/vaccines11040856","volume":"11","author":"F Jiang","year":"2023","unstructured":"Jiang F, Peng C, Cheng P, Wang J, Lian J, Gong W. PP19128R, a multiepitope vaccine designed to prevent latent tuberculosis infection, induced immune responses in silico and in vitro assays. Vaccines (Basel). 2023;11(4):856. https:\/\/doi.org\/10.3390\/vaccines11040856.","journal-title":"Vaccines (Basel)"},{"key":"243_CR45","doi-asserted-by":"publisher","first-page":"109728","DOI":"10.1016\/j.intimp.2023.109728","volume":"115","author":"F Jiang","year":"2023","unstructured":"Jiang F, Liu Y, Xue Y, Cheng P, Wang J, Lian J, et al. Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: a reverse vaccinology analysis. Int Immunopharmacol. 2023;115:109728. https:\/\/doi.org\/10.1016\/j.intimp.2023.109728.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"243_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41392-023-01381-z","volume":"8","author":"Z Yang","year":"2023","unstructured":"Yang Z, Zeng X, Zhao Y, Chen R. AlphaFold2 and its applications in the fields of biology and medicine. Signal Transduct Target Ther. 2023;8(1):115. https:\/\/doi.org\/10.1038\/s41392-023-01381-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"7889","key":"243_CR47","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41586-021-04184-w","volume":"600","author":"I Anishchenko","year":"2021","unstructured":"Anishchenko I, Pellock SJ, Chidyausiku TM, Ramelot TA, Ovchinnikov S, Hao J, et al. De novo protein design by deep network hallucination. Nature. 2021;600(7889):547\u201352. https:\/\/doi.org\/10.1038\/s41586-021-04184-w.","journal-title":"Nature"},{"issue":"6","key":"243_CR48","doi-asserted-by":"publisher","first-page":"e4653","DOI":"10.1002\/pro.4653","volume":"32","author":"CA Goverde","year":"2023","unstructured":"Goverde CA, Wolf B, Khakzad H, Rosset S, Correia BE. De novo protein design by inversion of the AlphaFold structure prediction network. Protein Sci. 2023;32(6):e4653. https:\/\/doi.org\/10.1002\/pro.4653.","journal-title":"Protein Sci"},{"key":"243_CR49","doi-asserted-by":"publisher","unstructured":"Zeng D, Xin J, Yang K, Guo S, Wang Q, Gao Y et al. A Hemagglutinin Stem Vaccine Designed Rationally by AlphaFold2 Confers Broad Protection against Influenza B Infection. Viruses. 2022;14(6). https:\/\/doi.org\/10.3390\/v14061305.","DOI":"10.3390\/v14061305"},{"key":"243_CR50","doi-asserted-by":"publisher","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A et al. Accurate structure prediction of biomolecular interactions with AlphaFold\u20093. Nature. 2024. https:\/\/doi.org\/10.1038\/s41586-024-07487-w","DOI":"10.1038\/s41586-024-07487-w"},{"issue":"Web Server issu","key":"243_CR51","doi-asserted-by":"publisher","first-page":"W363","DOI":"10.1093\/nar\/gki481","volume":"33","author":"D Schneidman-Duhovny","year":"2005","unstructured":"Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res. 2005;33(Web Server issue):W363\u20137. https:\/\/doi.org\/10.1093\/nar\/gki481.","journal-title":"Nucleic Acids Res"},{"key":"243_CR52","doi-asserted-by":"publisher","unstructured":"Bugnon M, R\u00f6hrig UF, Goullieux M, Perez MAS, Daina A, Michielin O et al. SwissDock 2024: major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina. Nucleic acids research. 2024. https:\/\/doi.org\/10.1093\/nar\/gkae300.","DOI":"10.1093\/nar\/gkae300"},{"issue":"20","key":"243_CR53","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","volume":"63","author":"DA Case","year":"2023","unstructured":"Case DA, Aktulga HM, Belfon K, Cerutti DS, Cisneros GA, Cruzeiro VWD, et al. AmberTools. J Chem Inf Model. 2023;63(20):6183\u201391. https:\/\/doi.org\/10.1021\/acs.jcim.3c01153.","journal-title":"J Chem Inf Model"},{"key":"243_CR54","unstructured":"GROMACS. GROMACS 2024.2 release notes. GROMACS. 2024. https:\/\/manual.gromacs.org\/2024.2\/release-notes\/2024\/2024.2.html. Accessed 15 May 2024."},{"issue":"7873","key":"243_CR55","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583\u20139. https:\/\/doi.org\/10.1038\/s41586-021-03819-2.","journal-title":"Nature"},{"issue":"D1","key":"243_CR56","doi-asserted-by":"publisher","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","volume":"50","author":"M Varadi","year":"2022","unstructured":"Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022;50(D1):D439\u201344. https:\/\/doi.org\/10.1093\/nar\/gkab1061.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"243_CR57","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638\u201346. https:\/\/doi.org\/10.1093\/nar\/gkac1000.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"243_CR58","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","volume":"49","author":"D Szklarczyk","year":"2021","unstructured":"Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res. 2021;49(D1):D605\u201312. https:\/\/doi.org\/10.1093\/nar\/gkaa1074.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"243_CR59","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607\u201313. https:\/\/doi.org\/10.1093\/nar\/gky1131.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"243_CR60","doi-asserted-by":"publisher","first-page":"e9862","DOI":"10.1371\/journal.pone.0009862","volume":"5","author":"N Rapin","year":"2010","unstructured":"Rapin N, Lund O, Bernaschi M, Castiglione F. Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS ONE. 2010;5(4):e9862. https:\/\/doi.org\/10.1371\/journal.pone.0009862.","journal-title":"PLoS ONE"},{"key":"243_CR61","doi-asserted-by":"publisher","first-page":"998262","DOI":"10.3389\/fimmu.2022.998262","volume":"13","author":"P Stolfi","year":"2022","unstructured":"Stolfi P, Castiglione F, Mastrostefano E, Di Biase I, Di Biase S, Palmieri G, et al. In-silico evaluation of adenoviral COVID-19 vaccination protocols: assessment of immunological memory up to 6 months after the third dose. Front Immunol. 2022;13:998262. https:\/\/doi.org\/10.3389\/fimmu.2022.998262.","journal-title":"Front Immunol"},{"key":"243_CR62","doi-asserted-by":"publisher","unstructured":"Ragone C, Manolio C, Cavalluzzo B, Mauriello A, Tornesello ML, Buonaguro FM et al. Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs). J Immunother Cancer. 2021;9(5). https:\/\/doi.org\/10.1136\/jitc-2021-002694.","DOI":"10.1136\/jitc-2021-002694"},{"issue":"4","key":"243_CR63","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/prot.20264","volume":"57","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Skolnick J. Scoring function for automated assessment of protein structure template quality. Proteins. 2004;57(4):702\u201310. https:\/\/doi.org\/10.1002\/prot.20264.","journal-title":"Proteins"},{"key":"243_CR64","doi-asserted-by":"publisher","unstructured":"Mustafa AS. Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins. Vaccines (Basel). 2021;9(1). https:\/\/doi.org\/10.3390\/vaccines9010027.","DOI":"10.3390\/vaccines9010027"},{"issue":"6","key":"243_CR65","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.tube.2008.05.002","volume":"88","author":"N Ganguly","year":"2008","unstructured":"Ganguly N, Siddiqui I, Sharma P. Role of M. tuberculosis RD-1 region encoded secretory proteins in protective response and virulence. Tuberculosis (Edinb). 2008;88(6):510\u20137. https:\/\/doi.org\/10.1016\/j.tube.2008.05.002.","journal-title":"Tuberculosis (Edinb)"},{"issue":"21","key":"243_CR66","doi-asserted-by":"publisher","first-page":"12420","DOI":"10.1073\/pnas.1635213100","volume":"100","author":"T Hsu","year":"2003","unstructured":"Hsu T, Hingley-Wilson SM, Chen B, Chen M, Dai AZ, Morin PM, et al. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci USA. 2003;100(21):12420\u20135. https:\/\/doi.org\/10.1073\/pnas.1635213100.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"30","key":"243_CR67","doi-asserted-by":"publisher","first-page":"10676","DOI":"10.1073\/pnas.0504922102","volume":"102","author":"SM Fortune","year":"2005","unstructured":"Fortune SM, Jaeger A, Sarracino DA, Chase MR, Sassetti CM, Sherman DR, et al. Mutually dependent secretion of proteins required for mycobacterial virulence. Proc Natl Acad Sci USA. 2005;102(30):10676\u201381. https:\/\/doi.org\/10.1073\/pnas.0504922102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"243_CR68","doi-asserted-by":"publisher","first-page":"e1000507","DOI":"10.1371\/journal.ppat.1000507","volume":"5","author":"W Bitter","year":"2009","unstructured":"Bitter W, Houben EN, Bottai D, Brodin P, Brown EJ, Cox JS, et al. Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog. 2009;5(10):e1000507. https:\/\/doi.org\/10.1371\/journal.ppat.1000507.","journal-title":"PLoS Pathog"},{"issue":"1","key":"243_CR69","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1086\/345862","volume":"187","author":"KN Lewis","year":"2003","unstructured":"Lewis KN, Liao R, Guinn KM, Hickey MJ, Smith S, Behr MA, et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Gu\u00e9rin attenuation. J Infect Dis. 2003;187(1):117\u201323. https:\/\/doi.org\/10.1086\/345862.","journal-title":"J Infect Dis"},{"issue":"24","key":"243_CR70","doi-asserted-by":"publisher","first-page":"21598","DOI":"10.1074\/jbc.M201625200","volume":"277","author":"PS Renshaw","year":"2002","unstructured":"Renshaw PS, Panagiotidou P, Whelan A, Gordon SV, Hewinson RG, Williamson RA, et al. Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterization of the structural properties of ESAT-6, CFP-10, and the ESAT-6*CFP-10 complex. Implications for pathogenesis and virulence. J Biol Chem. 2002;277(24):21598\u2013603. https:\/\/doi.org\/10.1074\/jbc.M201625200.","journal-title":"J Biol Chem"},{"issue":"14","key":"243_CR71","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1038\/sj.emboj.7600732","volume":"24","author":"PS Renshaw","year":"2005","unstructured":"Renshaw PS, Lightbody KL, Veverka V, Muskett FW, Kelly G, Frenkiel TA, et al. Structure and function of the complex formed by the tuberculosis virulence factors CFP-10 and ESAT-6. Embo j. 2005;24(14):2491\u20138. https:\/\/doi.org\/10.1038\/sj.emboj.7600732.","journal-title":"Embo j"},{"issue":"3","key":"243_CR72","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1046\/j.1365-2958.2002.03237.x","volume":"46","author":"AS Pym","year":"2002","unstructured":"Pym AS, Brodin P, Brosch R, Huerre M, Cole ST. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol. 2002;46(3):709\u201317. https:\/\/doi.org\/10.1046\/j.1365-2958.2002.03237.x.","journal-title":"Mol Microbiol"},{"issue":"1","key":"243_CR73","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1128\/iai.68.1.214-220.2000","volume":"68","author":"RL Skj\u00f8t","year":"2000","unstructured":"Skj\u00f8t RL, Oettinger T, Rosenkrands I, Ravn P, Brock I, Jacobsen S, et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun. 2000;68(1):214\u201320. https:\/\/doi.org\/10.1128\/iai.68.1.214-220.2000.","journal-title":"Infect Immun"},{"issue":"2","key":"243_CR74","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1128\/cdli.7.2.155-160.2000","volume":"7","author":"LA van Pinxteren","year":"2000","unstructured":"van Pinxteren LA, Ravn P, Agger EM, Pollock J, Andersen P. Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol. 2000;7(2):155\u201360. https:\/\/doi.org\/10.1128\/cdli.7.2.155-160.2000.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"3","key":"243_CR75","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1128\/cdli.8.3.571-578.2001","volume":"8","author":"HM Vordermeier","year":"2001","unstructured":"Vordermeier HM, Whelan A, Cockle PJ, Farrant L, Palmer N, Hewinson RG. Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle. Clin Diagn Lab Immunol. 2001;8(3):571\u20138. https:\/\/doi.org\/10.1128\/cdli.8.3.571-578.2001.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"11","key":"243_CR76","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.tim.2004.09.007","volume":"12","author":"P Brodin","year":"2004","unstructured":"Brodin P, Rosenkrands I, Andersen P, Cole ST, Brosch R. ESAT-6 proteins: protective antigens and virulence factors? Trends Microbiol. 2004;12(11):500\u20138. https:\/\/doi.org\/10.1016\/j.tim.2004.09.007.","journal-title":"Trends Microbiol"},{"issue":"3","key":"243_CR77","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1086\/314640","volume":"179","author":"P Ravn","year":"1999","unstructured":"Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA, et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis. 1999;179(3):637\u201345. https:\/\/doi.org\/10.1086\/314640.","journal-title":"J Infect Dis"},{"issue":"8","key":"243_CR78","first-page":"556","volume":"13","author":"M Hemmati","year":"2011","unstructured":"Hemmati M, Seghatoleslam A, Rasti M, Ebadat S, Mosavari N, Habibagahi M, et al. Expression and Purification of Recombinant Mycobacterium Tuberculosis (TB) Antigens, ESAT-6, CFP-10 and ESAT- 6\/CFP-10 and Their Diagnosis Potential for Detection of TB Patients. Iran Red Crescent Med J. 2011;13(8):556\u201363.","journal-title":"Iran Red Crescent Med J"},{"issue":"5","key":"243_CR79","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1128\/jcm.43.5.2070-2074.2005","volume":"43","author":"PC Hill","year":"2005","unstructured":"Hill PC, Jackson-Sillah D, Fox A, Franken KL, Lugos MD, Jeffries DJ, et al. ESAT-6\/CFP-10 fusion protein and peptides for optimal diagnosis of mycobacterium tuberculosis infection by ex vivo enzyme-linked immunospot assay in the Gambia. J Clin Microbiol. 2005;43(5):2070\u20134. https:\/\/doi.org\/10.1128\/jcm.43.5.2070-2074.2005.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"243_CR80","doi-asserted-by":"publisher","first-page":"e0152483","DOI":"10.1371\/journal.pone.0152483","volume":"11","author":"M Suzukawa","year":"2016","unstructured":"Suzukawa M, Akashi S, Nagai H, Nagase H, Nakamura H, Matsui H, et al. Combined analysis of IFN-\u03b3, IL-2, IL-5, IL-10, IL-1RA and MCP-1 in QFT supernatant is useful for distinguishing active tuberculosis from latent infection. PLoS One. 2016;11(4):e0152483. https:\/\/doi.org\/10.1371\/journal.pone.0152483.","journal-title":"PLoS One"},{"key":"243_CR81","doi-asserted-by":"publisher","first-page":"1345510","DOI":"10.3389\/fmmed.2024.1345510","volume":"4","author":"AM Rapulana","year":"2024","unstructured":"Rapulana AM, Mpotje T, Baiyegunhi OO, Ndlovu H, Smit TK, McHugh TD, et al. Combined analysis of host IFN-\u03b3, IL-2 and IP-10 as potential LTBI biomarkers in ESAT-6\/CFP-10 stimulated blood. Front Mol Med. 2024;4:1345510. https:\/\/doi.org\/10.3389\/fmmed.2024.1345510.","journal-title":"Front Mol Med"},{"issue":"22","key":"243_CR82","doi-asserted-by":"publisher","first-page":"13001","DOI":"10.1073\/pnas.2235593100","volume":"100","author":"SA Stanley","year":"2003","unstructured":"Stanley SA, Raghavan S, Hwang WW, Cox JS. Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc Natl Acad Sci USA. 2003;100(22):13001\u20136. https:\/\/doi.org\/10.1073\/pnas.2235593100.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"243_CR83","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s10517-021-05288-z","volume":"171","author":"SN Belogorodtsev","year":"2021","unstructured":"Belogorodtsev SN, Nemkova EK, Stavitskaya NV, Schwartz YS. Pathogenic Effects of M. tuberculosis-Specific Proteins ESAT-6 and CFP-10 in Macrophage Culture and in 3D-Granulemogenesis Model In Vitro. Bull Exp Biol Med. 2021;171(5):656\u201360. https:\/\/doi.org\/10.1007\/s10517-021-05288-z.","journal-title":"Bull Exp Biol Med."},{"issue":"4","key":"243_CR84","first-page":"296","volume":"41","author":"A Seghatoleslam","year":"2016","unstructured":"Seghatoleslam A, Hemmati M, Ebadat S, Movahedi B, Mostafavi-Pour Z. Macrophage immune response suppression by recombinant Mycobacterium tuberculosis antigens, the ESAT-6, CFP-10, and ESAT-6\/CFP-10 fusion proteins. Iran J Med Sci. 2016;41(4):296\u2013304.","journal-title":"Iran J Med Sci"},{"issue":"11","key":"243_CR85","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20041690","volume":"200","author":"AB Kamath","year":"2004","unstructured":"Kamath AB, Woodworth J, Xiong X, Taylor C, Weng Y, Behar SM. Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection. J Exp Med. 2004;200(11):1479\u201389. https:\/\/doi.org\/10.1084\/jem.20041690.","journal-title":"J Exp Med"},{"issue":"1","key":"243_CR86","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13063-017-2354-0","volume":"19","author":"J Hussein","year":"2018","unstructured":"Hussein J, Zewdie M, Yamuah L, Bedru A, Abebe M, Dagnew AF, et al. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1\/IC31\u00ae in people living in a TB-endemic area. Trials. 2018;19(1):24. https:\/\/doi.org\/10.1186\/s13063-017-2354-0.","journal-title":"Trials"},{"issue":"6","key":"243_CR87","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jmii.2014.03.005","volume":"48","author":"JB Lu","year":"2015","unstructured":"Lu JB, Chen BW, Wang GZ, Fu LL, Shen XB, Su C, et al. Recombinant tuberculosis vaccine AEC\/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection. J Microbiol Immunol Infect. 2015;48(6):597\u2013603. https:\/\/doi.org\/10.1016\/j.jmii.2014.03.005.","journal-title":"J Microbiol Immunol Infect"},{"issue":"33","key":"243_CR88","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","volume":"33","author":"AK Luabeya","year":"2015","unstructured":"Luabeya AK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, et al. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine. 2015;33(33):4130\u201340. https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.051.","journal-title":"Vaccine"},{"issue":"5","key":"243_CR89","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nm859","volume":"9","author":"AS Pym","year":"2003","unstructured":"Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med. 2003;9(5):533\u20139. https:\/\/doi.org\/10.1038\/nm859.","journal-title":"Nat Med"},{"key":"243_CR90","doi-asserted-by":"publisher","unstructured":"Vasina DV, Kleymenov DA, Manuylov VA, Mazunina EP, Koptev EY, Tukhovskaya EA et al. First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment. Vaccines (Basel). 2019;7(4). https:\/\/doi.org\/10.3390\/vaccines7040166.","DOI":"10.3390\/vaccines7040166"},{"issue":"1","key":"243_CR91","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.molimm.2014.06.026","volume":"62","author":"S Liu","year":"2014","unstructured":"Liu S, Jia H, Hou S, Zhang G, Xin T, Li H, et al. Recombinant TB10.4 of Mycobacterium bovis induces cytokine production in RAW264.7 macrophages through activation of the MAPK and NF-\u03baB pathways via TLR2. Mol Immunol. 2014;62(1):227\u201334. https:\/\/doi.org\/10.1016\/j.molimm.2014.06.026.","journal-title":"Mol Immunol."},{"issue":"34","key":"243_CR92","doi-asserted-by":"publisher","first-page":"29993","DOI":"10.1074\/jbc.M111.248732","volume":"286","author":"D Ilghari","year":"2011","unstructured":"Ilghari D, Lightbody KL, Veverka V, Waters LC, Muskett FW, Renshaw PS, et al. Solution structure of the Mycobacterium tuberculosis EsxG\u00b7EsxH complex: functional implications and comparisons with other M. tuberculosis Esx family complexes. J Biol Chem. 2011;286(34):29993\u201330002. https:\/\/doi.org\/10.1074\/jbc.M111.248732.","journal-title":"J Biol Chem"},{"issue":"10","key":"243_CR93","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.4049\/jimmunol.2300001","volume":"210","author":"D Mott","year":"2023","unstructured":"Mott D, Yang J, Baer C, Papavinasasundaram K, Sassetti CM, Behar SM. High Bacillary Burden and the ESX-1 Type VII Secretion System Promote MHC Class I Presentation by Mycobacterium tuberculosis-Infected Macrophages to CD8 T Cells. J Immunol (Baltimore, Md\u202f: 1950). 2023;210(10):1531\u201342. https:\/\/doi.org\/10.4049\/jimmunol.2300001.","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"6","key":"243_CR94","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.4049\/jimmunol.179.6.3973","volume":"179","author":"R Billeskov","year":"2007","unstructured":"Billeskov R, Vingsbo-Lundberg C, Andersen P, Dietrich J. Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1. J Immunol (Baltimore, Md\u202f: 1950). 2007;179(6):3973\u201381. https:\/\/doi.org\/10.4049\/jimmunol.179.6.3973.","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"key":"243_CR95","doi-asserted-by":"publisher","unstructured":"Sergeeva M, Romanovskaya-Romanko E, Zabolotnyh N, Pulkina A, Vasilyev K, Shurigina AP et al. Mucosal Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens Provides Protection against Mycobacterium tuberculosis in Mice and Guinea Pigs. Vaccines (Basel). 2021;9(4). https:\/\/doi.org\/10.3390\/vaccines9040394.","DOI":"10.3390\/vaccines9040394"},{"issue":"10","key":"243_CR96","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1128\/iai.70.10.5446-5453.2002","volume":"70","author":"RL Skj\u00f8t","year":"2002","unstructured":"Skj\u00f8t RL, Brock I, Arend SM, Munk ME, Theisen M, Ottenhoff TH, et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun. 2002;70(10):5446\u201353. https:\/\/doi.org\/10.1128\/iai.70.10.5446-5453.2002.","journal-title":"Infect Immun"},{"issue":"10","key":"243_CR97","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.4049\/jimmunol.174.10.6332","volume":"174","author":"J Dietrich","year":"2005","unstructured":"Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM, et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol (Baltimore, Md\u202f: 1950). 2005;174(10):6332\u20139.","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"4","key":"243_CR98","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000525136","volume":"31","author":"HA Safar","year":"2022","unstructured":"Safar HA, Mustafa AS, Amoudy HA, El-Hashim A. The Effect of Delivery Systems on the Induction of T Helper 1 Cell Response to an ESAT6-Like Protein Rv3619c and Identification of Its Immunodominant Peptides. Med Princ Pract. 2022;31(4):359\u201367. https:\/\/doi.org\/10.1159\/000525136.","journal-title":"Med Princ Pract"},{"issue":"11","key":"243_CR99","doi-asserted-by":"publisher","first-page":"7948","DOI":"10.4049\/jimmunol.181.11.7948","volume":"181","author":"S Bertholet","year":"2008","unstructured":"Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol (Baltimore, Md\u202f: 1950). 2008;181(11):7948\u201357. https:\/\/doi.org\/10.4049\/jimmunol.181.11.7948.","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"2","key":"243_CR100","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1742-4658.2010.07958.x","volume":"278","author":"A Mahmood","year":"2011","unstructured":"Mahmood A, Srivastava S, Tripathi S, Ansari MA, Owais M, Arora A. Molecular characterization of secretory proteins Rv3619c and Rv3620c from Mycobacterium tuberculosis H37Rv. FEBS J. 2011;278(2):341\u201353. https:\/\/doi.org\/10.1111\/j.1742-4658.2010.07958.x.","journal-title":"FEBS J"},{"issue":"2","key":"243_CR101","doi-asserted-by":"publisher","first-page":"e0228381","DOI":"10.1371\/journal.pone.0228381","volume":"15","author":"HA Safar","year":"2020","unstructured":"Safar HA, Mustafa AS, Amoudy HA, El-Hashim A. The effect of adjuvants and delivery systems on Th1, Th2, Th17 and Treg cytokine responses in mice immunized with Mycobacterium tuberculosis-specific proteins. PLoS One. 2020;15(2):e0228381. https:\/\/doi.org\/10.1371\/journal.pone.0228381.","journal-title":"PLoS One"},{"issue":"19","key":"243_CR102","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1128\/jb.187.19.6603-6611.2005","volume":"187","author":"L Nguyen","year":"2005","unstructured":"Nguyen L, Chinnapapagari S, Thompson CJ. FbpA-Dependent biosynthesis of trehalose dimycolate is required for the intrinsic multidrug resistance, cell wall structure, and colonial morphology of Mycobacterium smegmatis. J Bacteriol. 2005;187(19):6603\u201311. https:\/\/doi.org\/10.1128\/jb.187.19.6603-6611.2005.","journal-title":"J Bacteriol"},{"issue":"5317","key":"243_CR103","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1126\/science.276.5317.1420","volume":"276","author":"JT Belisle","year":"1997","unstructured":"Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science. 1997;276(5317):1420\u20132. https:\/\/doi.org\/10.1126\/science.276.5317.1420.","journal-title":"Science"},{"issue":"9","key":"243_CR104","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/eji.201343454","volume":"43","author":"OB Dintwe","year":"2013","unstructured":"Dintwe OB, Day CL, Smit E, Nemes E, Gray C, Tameris M, et al. Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function. Eur J Immunol. 2013;43(9):2409\u201320. https:\/\/doi.org\/10.1002\/eji.201343454.","journal-title":"Eur J Immunol"},{"issue":"4","key":"243_CR105","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1128\/mr.56.4.648-661.1992","volume":"56","author":"HG Wiker","year":"1992","unstructured":"Wiker HG, Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev. 1992;56(4):648\u201361. https:\/\/doi.org\/10.1128\/mr.56.4.648-661.1992.","journal-title":"Microbiol Rev"},{"issue":"3","key":"243_CR106","first-page":"63","volume":"62","author":"A Zlotta","year":"1994","unstructured":"Zlotta A, Drowart A, van Vooren JP, Simon J, Schulman CC, Huygen K. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer. Acta Urol Belg. 1994;62(3):63\u20138.","journal-title":"Acta Urol Belg"},{"key":"243_CR107","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.micpath.2017.08.040","volume":"112","author":"M Karbalaei Zadeh Babaki","year":"2017","unstructured":"Karbalaei Zadeh Babaki M, Soleimanpour S, Rezaee SA. Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design. Microb Pathog. 2017;112:20\u20139. https:\/\/doi.org\/10.1016\/j.micpath.2017.08.040.","journal-title":"Microb Pathog"},{"issue":"6","key":"243_CR108","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1365-2958.2011.07792.x","volume":"81","author":"AA Elamin","year":"2011","unstructured":"Elamin AA, Stehr M, Spallek R, Rohde M, Singh M. The Mycobacterium tuberculosis Ag85A is a novel diacylglycerol acyltransferase involved in lipid body formation. Mol Microbiol. 2011;81(6):1577\u201392. https:\/\/doi.org\/10.1111\/j.1365-2958.2011.07792.x.","journal-title":"Mol Microbiol"},{"issue":"1","key":"243_CR109","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/iai.71.1.483-493.2003","volume":"71","author":"S D'Souza","year":"2003","unstructured":"D\u2019Souza S, Rosseels V, Romano M, Tanghe A, Denis O, Jurion F, et al. Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun. 2003;71(1):483\u201393. https:\/\/doi.org\/10.1128\/iai.71.1.483-493.2003.","journal-title":"Infect Immun"},{"issue":"6","key":"243_CR110","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.4049\/jimmunol.1500981","volume":"195","author":"AK Khera","year":"2015","unstructured":"Khera AK, Afkhami S, Lai R, Jeyanathan M, Zganiacz A, Mandur T, et al. Role of B cells in mucosal vaccine-induced protective CD8+ T cell immunity against pulmonary tuberculosis. J Immunol (Baltimore, Md\u202f: 1950). 2015;195(6):2900\u20137. https:\/\/doi.org\/10.4049\/jimmunol.1500981.","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"5","key":"243_CR111","doi-asserted-by":"publisher","first-page":"e854","DOI":"10.1002\/iid3.854","volume":"11","author":"N Wang","year":"2023","unstructured":"Wang N, Liang Y, Ma Q, Mi J, Xue Y, Yang Y, et al. Mechanisms of ag85a\/b DNA vaccine conferred immunotherapy and recovery from Mycobacterium tuberculosis-induced injury. Immun Inflamm Dis. 2023;11(5):e854. https:\/\/doi.org\/10.1002\/iid3.854.","journal-title":"Immun Inflamm Dis"},{"issue":"18","key":"243_CR112","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1016\/j.vaccine.2012.02.036","volume":"30","author":"MJ Brennan","year":"2012","unstructured":"Brennan MJ, Clagett B, Fitzgerald H, Chen V, Williams A, Izzo AA, et al. Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine. 2012;30(18):2811\u201323. https:\/\/doi.org\/10.1016\/j.vaccine.2012.02.036.","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"243_CR113","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/s1472-9792(12)70005-7","volume":"92","author":"MJ Brennan","year":"2012","unstructured":"Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb). 2012;92(Suppl 1):S6-13. https:\/\/doi.org\/10.1016\/s1472-9792(12)70005-7.","journal-title":"Tuberculosis (Edinb)"},{"issue":"16","key":"243_CR114","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1016\/j.vaccine.2005.12.066","volume":"24","author":"M Romano","year":"2006","unstructured":"Romano M, D\u2019Souza S, Adnet PY, Laali R, Jurion F, Palfliet K, et al. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine. 2006;24(16):3353\u201364. https:\/\/doi.org\/10.1016\/j.vaccine.2005.12.066.","journal-title":"Vaccine."},{"issue":"8","key":"243_CR115","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1128\/iai.64.8.3038-3047.1996","volume":"64","author":"G Harth","year":"1996","unstructured":"Harth G, Lee BY, Wang J, Clemens DL, Horwitz MA. Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis. Infect Immun. 1996;64(8):3038\u201347. https:\/\/doi.org\/10.1128\/iai.64.8.3038-3047.1996.","journal-title":"Infect Immun"},{"issue":"5","key":"243_CR116","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1073\/pnas.92.5.1530","volume":"92","author":"MA Horwitz","year":"1995","unstructured":"Horwitz MA, Lee BW, Dillon BJ, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 1995;92(5):1530\u20134. https:\/\/doi.org\/10.1073\/pnas.92.5.1530.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"32","key":"243_CR117","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1016\/j.vaccine.2019.06.078","volume":"37","author":"C Wang","year":"2019","unstructured":"Wang C, Lu J, Du W, Wang G, Li X, Shen X, et al. Ag85b\/ESAT6-CFP10 adjuvanted with aluminum\/poly-IC effectively protects guinea pigs from latent mycobacterium tuberculosis infection. Vaccine. 2019;37(32):4477\u201384. https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.078.","journal-title":"Vaccine"},{"issue":"1","key":"243_CR118","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41541-024-00897-x","volume":"9","author":"V Rungelrath","year":"2024","unstructured":"Rungelrath V, Ahmed M, Hicks L, Miller SM, Ryter KT, Montgomery K, et al. Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses. NPJ vaccines. 2024;9(1):100. https:\/\/doi.org\/10.1038\/s41541-024-00897-x.","journal-title":"NPJ vaccines"},{"issue":"5","key":"243_CR119","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1128\/IAI.69.5.2773-2778.2001","volume":"69","author":"A Weinrich Olsen","year":"2001","unstructured":"Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun. 2001;69(5):2773\u20138. https:\/\/doi.org\/10.1128\/IAI.69.5.2773-2778.2001.","journal-title":"Infect Immun"},{"issue":"8","key":"243_CR120","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1128\/iai.73.8.4676-4683.2005","volume":"73","author":"MA Horwitz","year":"2005","unstructured":"Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun. 2005;73(8):4676\u201383. https:\/\/doi.org\/10.1128\/iai.73.8.4676-4683.2005.","journal-title":"Infect Immun"},{"issue":"11","key":"243_CR121","doi-asserted-by":"publisher","first-page":"5816","DOI":"10.1021\/pr1005873","volume":"9","author":"LM Wolfe","year":"2010","unstructured":"Wolfe LM, Mahaffey SB, Kruh NA, Dobos KM. Proteomic definition of the cell wall of Mycobacterium tuberculosis. J Proteome Res. 2010;9(11):5816\u201326. https:\/\/doi.org\/10.1021\/pr1005873.","journal-title":"J Proteome Res"},{"issue":"6685","key":"243_CR122","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/31159","volume":"393","author":"ST Cole","year":"1998","unstructured":"Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393(6685):537\u201344. https:\/\/doi.org\/10.1038\/31159.","journal-title":"Nature"},{"issue":"4","key":"243_CR123","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1462-5822.2004.00484.x","volume":"7","author":"Y Li","year":"2005","unstructured":"Li Y, Miltner E, Wu M, Petrofsky M, Bermudez LE. A Mycobacterium avium PPE gene is associated with the ability of the bacterium to grow in macrophages and virulence in mice. Cell Microbiol. 2005;7(4):539\u201348. https:\/\/doi.org\/10.1111\/j.1462-5822.2004.00484.x.","journal-title":"Cell Microbiol"},{"issue":"3","key":"243_CR124","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.micinf.2006.11.013","volume":"9","author":"KN Balaji","year":"2007","unstructured":"Balaji KN, Goyal G, Narayana Y, Srinivas M, Chaturvedi R, Mohammad S. Apoptosis triggered by Rv1818c, a PE family gene from Mycobacterium tuberculosis is regulated by mitochondrial intermediates in T cells. Microbes Infect. 2007;9(3):271\u201381. https:\/\/doi.org\/10.1016\/j.micinf.2006.11.013.","journal-title":"Microbes Infect"},{"issue":"2","key":"243_CR125","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1074\/jbc.M604379200","volume":"282","author":"S Basu","year":"2007","unstructured":"Basu S, Pathak SK, Banerjee A, Pathak S, Bhattacharyya A, Yang Z, et al. Execution of macrophage apoptosis by PE_PGRS33 of Mycobacterium tuberculosis is mediated by Toll-like receptor 2-dependent release of tumor necrosis factor-alpha. J Biol Chem. 2007;282(2):1039\u201350. https:\/\/doi.org\/10.1074\/jbc.M604379200.","journal-title":"J Biol Chem"},{"issue":"1","key":"243_CR126","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.micinf.2005.06.021","volume":"8","author":"V Dheenadhayalan","year":"2006","unstructured":"Dheenadhayalan V, Delogu G, Brennan MJ. Expression of the PE_PGRS 33 protein in Mycobacterium smegmatis triggers necrosis in macrophages and enhanced mycobacterial survival. Microbes Infect. 2006;8(1):262\u201372. https:\/\/doi.org\/10.1016\/j.micinf.2005.06.021.","journal-title":"Microbes Infect"},{"issue":"9","key":"243_CR127","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.4049\/jimmunol.1000773","volume":"186","author":"S Nair","year":"2011","unstructured":"Nair S, Pandey AD, Mukhopadhyay S. The PPE18 protein of Mycobacterium tuberculosis inhibits NF-\u03baB\/rel-mediated proinflammatory cytokine production by upregulating and phosphorylating suppressor of cytokine signaling 3 protein. J Immunol (Baltimore, Md\u202f: 1950). 2011;186(9):5413\u201324. https:\/\/doi.org\/10.4049\/jimmunol.1000773.","journal-title":"J Immunol (Baltimore, Md : 1950)."},{"issue":"3","key":"243_CR128","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/eji.201848071","volume":"51","author":"K Dolasia","year":"2021","unstructured":"Dolasia K, Nazar F, Mukhopadhyay S. Mycobacterium tuberculosis PPE18 protein inhibits MHC class II antigen presentation and B cell response in mice. Eur J Immunol. 2021;51(3):603\u201319. https:\/\/doi.org\/10.1002\/eji.201848071.","journal-title":"Eur J Immunol"},{"issue":"12","key":"243_CR129","doi-asserted-by":"publisher","first-page":"e52601","DOI":"10.1371\/journal.pone.0052601","volume":"7","author":"KH Bhat","year":"2012","unstructured":"Bhat KH, Ahmed A, Kumar S, Sharma P, Mukhopadhyay S. Role of PPE18 protein in intracellular survival and pathogenicity of Mycobacterium tuberculosis in mice. PLoS One. 2012;7(12):e52601. https:\/\/doi.org\/10.1371\/journal.pone.0052601.","journal-title":"PLoS One"},{"issue":"6","key":"243_CR130","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1128\/iai.67.6.2941-2950.1999","volume":"67","author":"DC Dillon","year":"1999","unstructured":"Dillon DC, Alderson MR, Day CH, Lewinsohn DM, Coler R, Bement T, et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun. 1999;67(6):2941\u201350. https:\/\/doi.org\/10.1128\/iai.67.6.2941-2950.1999.","journal-title":"Infect Immun"},{"issue":"9","key":"243_CR131","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1128\/iai.00520-12","volume":"80","author":"DJ Bretl","year":"2012","unstructured":"Bretl DJ, He H, Demetriadou C, White MJ, Penoske RM, Salzman NH, et al. MprA and DosR coregulate a Mycobacterium tuberculosis virulence operon encoding Rv1813c and Rv1812c. Infect Immun. 2012;80(9):3018\u201333. https:\/\/doi.org\/10.1128\/iai.00520-12.","journal-title":"Infect Immun"},{"issue":"3","key":"243_CR132","doi-asserted-by":"publisher","first-page":"e0106623","DOI":"10.1128\/spectrum.01066-23","volume":"11","author":"M Martin","year":"2023","unstructured":"Martin M, deVisch A, Boudehen YM, Barthe P, Gutierrez C, Turapov O, et al. A Mycobacterium tuberculosis Effector Targets Mitochondrion, Controls Energy Metabolism, and Limits Cytochrome c Exit. Microbiol Spectr. 2023;11(3):e0106623. https:\/\/doi.org\/10.1128\/spectrum.01066-23.","journal-title":"Microbiol Spectr"},{"issue":"3","key":"243_CR133","doi-asserted-by":"publisher","first-page":"e0122560","DOI":"10.1371\/journal.pone.0122560","volume":"10","author":"X Wang","year":"2015","unstructured":"Wang X, Zhang J, Liang J, Zhang Y, Teng X, Yuan X, et al. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-\u03b3+ IL-2+ CD4+ and IFN-\u03b3+ CD8+ T cells. PLoS One. 2015;10(3):e0122560. https:\/\/doi.org\/10.1371\/journal.pone.0122560.","journal-title":"PLoS One"},{"issue":"8","key":"243_CR134","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1128\/iai.67.8.3998-4007.1999","volume":"67","author":"YA Skeiky","year":"1999","unstructured":"Skeiky YA, Lodes MJ, Guderian JA, Mohamath R, Bement T, Alderson MR, et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun. 1999;67(8):3998\u20134007. https:\/\/doi.org\/10.1128\/iai.67.8.3998-4007.1999.","journal-title":"Infect Immun"},{"key":"243_CR135","doi-asserted-by":"publisher","first-page":"104897","DOI":"10.1016\/j.ebiom.2023.104897","volume":"99","author":"E Ishida","year":"2024","unstructured":"Ishida E, Corrigan DT, Chen T, Liu Y, Kim RS, Song L, et al. Mucosal and systemic antigen-specific antibody responses correlate with protection against active tuberculosis in nonhuman primates. EBioMedicine. 2024;99:104897. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104897.","journal-title":"EBioMedicine"},{"issue":"5\u20136","key":"243_CR136","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.micpath.2007.05.010","volume":"43","author":"ML Ribeiro-Guimar\u00e3es","year":"2007","unstructured":"Ribeiro-Guimar\u00e3es ML, Pessolani MC. Comparative genomics of mycobacterial proteases. Microb Pathog. 2007;43(5\u20136):173\u20138. https:\/\/doi.org\/10.1016\/j.micpath.2007.05.010.","journal-title":"Microb Pathog"},{"key":"243_CR137","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/1471-2105-8-361","volume":"8","author":"HH Bui","year":"2007","unstructured":"Bui HH, Sidney J, Li W, Fusseder N, Sette A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics. 2007;8:361. https:\/\/doi.org\/10.1186\/1471-2105-8-361.","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"243_CR138","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.3892\/mmr.2018.8758","volume":"17","author":"H Jiang","year":"2018","unstructured":"Jiang H, Luo TL, Kang J, Xu ZK, Wang LM. Expression of Rv2031c-Rv2626c fusion protein in Mycobacterium smegmatis enhances bacillary survival and modulates innate immunity in macrophages. Mol Med Rep. 2018;17(5):7307\u201312. https:\/\/doi.org\/10.3892\/mmr.2018.8758.","journal-title":"Mol Med Rep"},{"issue":"1","key":"243_CR139","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2567.2009.03196.x","volume":"130","author":"N Bashir","year":"2010","unstructured":"Bashir N, Kounsar F, Mukhopadhyay S, Hasnain SE. Mycobacterium tuberculosis conserved hypothetical protein rRv2626c modulates macrophage effector functions. Immunology. 2010;130(1):34\u201345. https:\/\/doi.org\/10.1111\/j.1365-2567.2009.03196.x.","journal-title":"Immunology"},{"issue":"2","key":"243_CR140","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1128\/IAI.01137-06","volume":"75","author":"V Roupie","year":"2007","unstructured":"Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL, et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun. 2007;75(2):941\u20139. https:\/\/doi.org\/10.1128\/IAI.01137-06.","journal-title":"Infect Immun"},{"issue":"4","key":"243_CR141","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1128\/jb.180.4.801-808.1998","volume":"180","author":"AF Cunningham","year":"1998","unstructured":"Cunningham AF, Spreadbury CL. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J Bacteriol. 1998;180(4):801\u20138. https:\/\/doi.org\/10.1128\/jb.180.4.801-808.1998.","journal-title":"J Bacteriol"},{"issue":"48\u201349","key":"243_CR142","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.1016\/j.vaccine.2005.03.056","volume":"23","author":"A Khera","year":"2005","unstructured":"Khera A, Singh R, Shakila H, Rao V, Dhar N, Narayanan PR, et al. Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis. Vaccine. 2005;23(48\u201349):5655\u201365. https:\/\/doi.org\/10.1016\/j.vaccine.2005.03.056.","journal-title":"Vaccine"},{"issue":"11","key":"243_CR143","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s10096-021-04246-x","volume":"40","author":"C Huang","year":"2021","unstructured":"Huang C, Pan L, Shen X, Tian H, Guo L, Zhang Z, et al. Hsp16.3 of mycobacterium tuberculosis in exosomes as a biomarker of tuberculosis. Eur J Clin Microbiol Infect Dis. 2021;40(11):2427\u201330. https:\/\/doi.org\/10.1007\/s10096-021-04246-x.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"12","key":"243_CR144","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1016\/j.ajpath.2017.08.014","volume":"187","author":"TW Foreman","year":"2017","unstructured":"Foreman TW, Veatch AV, LoBato DN, Didier PJ, Doyle-Meyers LA, Russell-Lodrigue KE, et al. Nonpathologic infection of macaques by an attenuated mycobacterial vaccine is not reactivated in the setting of HIV co-infection. Am J Pathol. 2017;187(12):2811\u201320. https:\/\/doi.org\/10.1016\/j.ajpath.2017.08.014.","journal-title":"Am J Pathol"},{"key":"243_CR145","doi-asserted-by":"publisher","first-page":"8533","DOI":"10.1038\/ncomms9533","volume":"6","author":"D Kaushal","year":"2015","unstructured":"Kaushal D, Foreman TW, Gautam US, Alvarez X, Adekambi T, Rangel-Moreno J, et al. Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis. Nat Commun. 2015;6:8533. https:\/\/doi.org\/10.1038\/ncomms9533.","journal-title":"Nat Commun"},{"issue":"6","key":"243_CR146","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.vaccine.2015.12.059","volume":"34","author":"S Sakthi","year":"2016","unstructured":"Sakthi S, Palaniyandi K, Gupta UD, Gupta P, Narayanan S. Lipoprotein LpqS deficient M. tuberculosis mutant is attenuated for virulence in vivo and shows protective efficacy better than BCG in guinea pigs. Vaccine. 2016;34(6):735\u201343. https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.059.","journal-title":"Vaccine."},{"issue":"1","key":"243_CR147","doi-asserted-by":"publisher","first-page":"15230","DOI":"10.1038\/s41598-017-15458-7","volume":"7","author":"BJ Kim","year":"2017","unstructured":"Kim BJ, Kim BR, Kook YH, Kim BJ. A temperature sensitive Mycobacterium paragordonae induces enhanced protective immune responses against mycobacterial infections in the mouse model. Sci Rep. 2017;7(1):15230. https:\/\/doi.org\/10.1038\/s41598-017-15458-7.","journal-title":"Sci Rep"},{"issue":"4","key":"243_CR148","doi-asserted-by":"publisher","first-page":"111142","DOI":"10.1016\/j.celrep.2022.111142","volume":"40","author":"J Lopez","year":"2022","unstructured":"Lopez J, Anna F, Authi\u00e9 P, Pawlik A, Ku MW, Blanc C, et al. A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4(+) T cell immunity. Cell Rep. 2022;40(4):111142. https:\/\/doi.org\/10.1016\/j.celrep.2022.111142.","journal-title":"Cell Rep"},{"issue":"5","key":"243_CR149","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.ymthe.2017.02.018","volume":"25","author":"Z Hu","year":"2017","unstructured":"Hu Z, Wong KW, Zhao HM, Wen HL, Ji P, Ma H, et al. Sendai Virus Mucosal Vaccination Establishes Lung-Resident Memory CD8 T Cell Immunity and Boosts BCG-Primed Protection against TB in Mice. Mol Ther. 2017;25(5):1222\u201333. https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.018.","journal-title":"Mol Ther"},{"issue":"1","key":"243_CR150","doi-asserted-by":"publisher","first-page":"2300463","DOI":"10.1080\/22221751.2023.2300463","volume":"13","author":"Z Hu","year":"2024","unstructured":"Hu Z, Xia J, Wu J, Zhao H, Ji P, Gu L, et al. A multistage Sendai virus vaccine incorporating latency-associated antigens induces protection against acute and latent tuberculosis. Emerg Microbes Infect. 2024;13(1):2300463. https:\/\/doi.org\/10.1080\/22221751.2023.2300463.","journal-title":"Emerg Microbes Infect"},{"issue":"24","key":"243_CR151","doi-asserted-by":"publisher","first-page":"10587","DOI":"10.1007\/s00253-015-6962-x","volume":"99","author":"X Yuan","year":"2015","unstructured":"Yuan X, Teng X, Jing Y, Ma J, Tian M, Yu Q, et al. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection. Appl Microbiol Biotechnol. 2015;99(24):10587\u201395. https:\/\/doi.org\/10.1007\/s00253-015-6962-x.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"11","key":"243_CR152","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1016\/j.celrep.2017.02.057","volume":"18","author":"MI Groschel","year":"2017","unstructured":"Groschel MI, Sayes F, Shin SJ, Frigui W, Pawlik A, Orgeur M, et al. Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection. Cell Rep. 2017;18(11):2752\u201365. https:\/\/doi.org\/10.1016\/j.celrep.2017.02.057.","journal-title":"Cell Rep"},{"issue":"1","key":"243_CR153","doi-asserted-by":"publisher","first-page":"15824","DOI":"10.1038\/s41598-022-20017-w","volume":"12","author":"KW Kwon","year":"2022","unstructured":"Kwon KW, Aceves-S\u00e1nchez MJ, Segura-Cerda CA, Choi E, Bielefeldt-Ohmann H, Shin SJ, et al. BCG\u0394BCG1419c increased memory CD8(+) T cell-associated immunogenicity and mitigated pulmonary inflammation compared with BCG in a model of chronic tuberculosis. Sci Rep. 2022;12(1):15824. https:\/\/doi.org\/10.1038\/s41598-022-20017-w.","journal-title":"Sci Rep"},{"issue":"1","key":"243_CR154","doi-asserted-by":"publisher","first-page":"12417","DOI":"10.1038\/s41598-021-91993-8","volume":"11","author":"MJ Aceves-S\u00e1nchez","year":"2021","unstructured":"Aceves-S\u00e1nchez MJ, Flores-Valdez MA, Pedroza-Rold\u00e1n C, Creissen E, Izzo L, Silva-Angulo F, et al. Vaccination with BCG\u0394BCG1419c protects against pulmonary and extrapulmonary TB and is safer than BCG. Sci Rep. 2021;11(1):12417. https:\/\/doi.org\/10.1038\/s41598-021-91993-8.","journal-title":"Sci Rep"},{"issue":"1","key":"243_CR155","doi-asserted-by":"publisher","first-page":"8582","DOI":"10.1038\/s41598-017-09119-y","volume":"7","author":"C Counoupas","year":"2017","unstructured":"Counoupas C, Pinto R, Nagalingam G, Britton WJ, Petrovsky N, Triccas JA. Delta inulin-based adjuvants promote the generation of polyfunctional CD4(+) T cell responses and protection against Mycobacterium tuberculosis infection. Sci Rep. 2017;7(1):8582. https:\/\/doi.org\/10.1038\/s41598-017-09119-y.","journal-title":"Sci Rep"},{"issue":"7","key":"243_CR156","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1080\/21645515.2016.1141159","volume":"12","author":"X Liu","year":"2016","unstructured":"Liu X, Peng J, Hu L, Luo Y, Niu H, Bai C, et al. A multistage mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis. Hum Vaccin Immunother. 2016;12(7):1670\u20137. https:\/\/doi.org\/10.1080\/21645515.2016.1141159.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"243_CR157","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/sji.12556","volume":"85","author":"F Li","year":"2017","unstructured":"Li F, Kang H, Li J, Zhang D, Zhang Y, Dannenberg AM Jr, et al. Subunit Vaccines Consisting of Antigens from Dormant and Replicating Bacteria Show Promising Therapeutic Effect against Mycobacterium Bovis BCG Latent Infection. Scand J Immunol. 2017;85(6):425\u201332. https:\/\/doi.org\/10.1111\/sji.12556.","journal-title":"Scand J Immunol"},{"key":"243_CR158","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ebiom.2017.07.005","volume":"22","author":"J Ma","year":"2017","unstructured":"Ma J, Teng X, Wang X, Fan X, Wu Y, Tian M, et al. A multistage subunit vaccine effectively protects mice against primary progressive tuberculosis, latency and reactivation. EBioMedicine. 2017;22:143\u201354. https:\/\/doi.org\/10.1016\/j.ebiom.2017.07.005.","journal-title":"EBioMedicine"},{"issue":"6","key":"243_CR159","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1080\/21645515.2015.1037057","volume":"11","author":"X Teng","year":"2015","unstructured":"Teng X, Tian M, Li J, Tan S, Yuan X, Yu Q, et al. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine. Hum Vaccin Immunother. 2015;11(6):1456\u201364. https:\/\/doi.org\/10.1080\/21645515.2015.1037057.","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"243_CR160","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.4049\/jimmunol.2000563","volume":"205","author":"C Aagaard","year":"2020","unstructured":"Aagaard C, Knudsen NPH, Sohn I, Izzo AA, Kim H, Kristiansen EH, et al. Immunization with mycobacterium tuberculosis-specific antigens bypasses T cell differentiation from prior bacillus calmette-gu\u00e9rin vaccination and improves protection in Mice. J Immunol (Baltimore, Md\u202f: 1950). 2020;205(8):2146\u201355. https:\/\/doi.org\/10.4049\/jimmunol.2000563.","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"1","key":"243_CR161","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1038\/s41467-021-26934-0","volume":"12","author":"JS Woodworth","year":"2021","unstructured":"Woodworth JS, Clemmensen HS, Battey H, Dijkman K, Lindenstr\u00f8m T, Laureano RS, et al. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Gu\u00e9rin. Nat Commun. 2021;12(1):6658. https:\/\/doi.org\/10.1038\/s41467-021-26934-0.","journal-title":"Nat Commun"},{"key":"243_CR162","doi-asserted-by":"publisher","first-page":"1047306","DOI":"10.3389\/fcimb.2022.1047306","volume":"12","author":"P Cheng","year":"2022","unstructured":"Cheng P, Xue Y, Wang J, Jia Z, Wang L, Gong W. Evaluation of the consistence between the results of immunoinformatics predictions and real-world animal experiments of a new tuberculosis vaccine MP3RT. Front Cell Infect Microbiol. 2022;12:1047306. https:\/\/doi.org\/10.3389\/fcimb.2022.1047306.","journal-title":"Front Cell Infect Microbiol"},{"key":"243_CR163","doi-asserted-by":"publisher","first-page":"603690","DOI":"10.3389\/fmedt.2020.603690","volume":"2","author":"CL Silva","year":"2020","unstructured":"Silva CL, Malardo T, Tahyra ASC. Immunotherapeutic Activities of a DNA Plasmid Carrying the Mycobacterial hsp65 Gene (DNAhsp65). Front Med Technol. 2020;2:603690. https:\/\/doi.org\/10.3389\/fmedt.2020.603690.","journal-title":"Front Med Technol"},{"issue":"4","key":"243_CR164","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1046\/j.1365-2567.1999.00840.x","volume":"97","author":"CL Silva","year":"1999","unstructured":"Silva CL, Bonato VL, Lima VM, Faccioli LH, Le\u00e3o SC. Characterization of the memory\/activated T cells that mediate the long-lived host response against tuberculosis after bacillus Calmette-Gu\u00e9rin or DNA vaccination. Immunology. 1999;97(4):573\u201381. https:\/\/doi.org\/10.1046\/j.1365-2567.1999.00840.x.","journal-title":"Immunology"},{"issue":"5","key":"243_CR165","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.4161\/hv.23417","volume":"9","author":"CR Z\u00e1rate-Blad\u00e9s","year":"2013","unstructured":"Z\u00e1rate-Blad\u00e9s CR, Rodrigues RF, Souza PR, Rios WM, Soares LS, Rosada RS, et al. Evaluation of the overall IFN-\u03b3 and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis. Hum Vaccin Immunother. 2013;9(5):1093\u2013103. https:\/\/doi.org\/10.4161\/hv.23417.","journal-title":"Hum Vaccin Immunother"},{"key":"243_CR166","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1479-0556-5-7","volume":"5","author":"ED Gon\u00e7alves","year":"2007","unstructured":"Gon\u00e7alves ED, Bonato VL, da Fonseca DM, Soares EG, Brand\u00e3o IT, Soares AP, et al. Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming. Genet Vaccines Ther. 2007;5:7. https:\/\/doi.org\/10.1186\/1479-0556-5-7.","journal-title":"Genet Vaccines Ther"},{"key":"243_CR167","doi-asserted-by":"publisher","unstructured":"Larsen SE, Erasmus JH, Reese VA, Pecor T, Archer J, Kandahar A et al. An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis. Vaccines (Basel). 2023;11(1). https:\/\/doi.org\/10.3390\/vaccines11010130.","DOI":"10.3390\/vaccines11010130"},{"key":"243_CR168","doi-asserted-by":"publisher","first-page":"102302","DOI":"10.1016\/j.tube.2022.102302","volume":"138","author":"M Rais","year":"2023","unstructured":"Rais M, Abdelaal H, Reese VA, Ferede D, Larsen SE, Pecor T, et al. Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen. Tuberculosis (Edinb). 2023;138:102302. https:\/\/doi.org\/10.1016\/j.tube.2022.102302.","journal-title":"Tuberculosis (Edinb)"},{"issue":"4","key":"243_CR169","first-page":"281","volume":"58","author":"EK Jagusztyn-Krynicka","year":"2009","unstructured":"Jagusztyn-Krynicka EK, Roszczenko P, Grabowska A. Impact of proteomics on anti-Mycobacterium tuberculosis (MTB) vaccine development. Pol J Microbiol. 2009;58(4):281\u20137.","journal-title":"Pol J Microbiol"},{"issue":"6","key":"243_CR170","first-page":"483","volume":"80","author":"AM Ginsberg","year":"2002","unstructured":"Ginsberg AM. What\u2019s new in tuberculosis vaccines? Bull World Health Organ. 2002;80(6):483\u20138.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"243_CR171","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1038\/s41598-017-03514-1","volume":"7","author":"SK Sharma","year":"2017","unstructured":"Sharma SK, Katoch K, Sarin R, Balambal R, Kumar Jain N, Patel N, et al. Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial. Sci Rep. 2017;7(1):3354. https:\/\/doi.org\/10.1038\/s41598-017-03514-1.","journal-title":"Sci Rep"},{"issue":"5","key":"243_CR172","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","volume":"24","author":"CF von Reyn","year":"2010","unstructured":"von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, et al. Prevention of tuberculosis in Bacille Calmette-Gu\u00e9rin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS. 2010;24(5):675\u201385. https:\/\/doi.org\/10.1097\/QAD.0b013e3283350f1b.","journal-title":"AIDS"},{"issue":"46","key":"243_CR173","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1016\/j.vaccine.2020.09.055","volume":"38","author":"P Munseri","year":"2020","unstructured":"Munseri P, Said J, Amour M, Magohe A, Matee M, Rees CA, et al. DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial. Vaccine. 2020;38(46):7239\u201345. https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.055.","journal-title":"Vaccine"},{"issue":"2","key":"243_CR174","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","volume":"379","author":"E Nemes","year":"2018","unstructured":"Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, et al. Prevention of M tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med. 2018;379(2):138\u201349. https:\/\/doi.org\/10.1056\/NEJMoa1714021.","journal-title":"N Engl J Med"},{"issue":"4","key":"243_CR175","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/s2213-2600(20)30319-2","volume":"9","author":"TA Day","year":"2021","unstructured":"Day TA, Penn-Nicholson A, Luabeya AKK, Fiore-Gartland A, Du Plessis N, Loxton AG, et al. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respir Med. 2021;9(4):373\u201386. https:\/\/doi.org\/10.1016\/s2213-2600(20)30319-2.","journal-title":"Lancet Respir Med"},{"issue":"9871","key":"243_CR176","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","volume":"381","author":"MD Tameris","year":"2013","unstructured":"Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(13)60177-4.","journal-title":"Lancet"},{"issue":"3","key":"243_CR177","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/s1473-3099(23)00501-7","volume":"24","author":"A Wajja","year":"2024","unstructured":"Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, et al. Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial. Lancet Infect Dis. 2024;24(3):285\u201396. https:\/\/doi.org\/10.1016\/s1473-3099(23)00501-7.","journal-title":"Lancet Infect Dis"},{"key":"243_CR178","doi-asserted-by":"publisher","unstructured":"Jeyanathan M, Fritz DK, Afkhami S, Aguirre E, Howie KJ, Zganiacz A et al. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI insight. 2022;7(3). https:\/\/doi.org\/10.1172\/jci.insight.155655.","DOI":"10.1172\/jci.insight.155655"},{"issue":"5\u20136","key":"243_CR179","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.ijmm.2014.05.006","volume":"304","author":"Y Singh","year":"2014","unstructured":"Singh Y, Kohli S, Sowpati DT, Rahman SA, Tyagi AK, Hasnain SE. Gene cooption in mycobacteria and search for virulence attributes: comparative proteomic analyses of Mycobacterium tuberculosis, Mycobacterium indicus pranii and other mycobacteria. Int J Med Microbiol. 2014;304(5\u20136):742\u20138. https:\/\/doi.org\/10.1016\/j.ijmm.2014.05.006.","journal-title":"Int J Med Microbiol"},{"issue":"8","key":"243_CR180","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.ijmm.2018.08.008","volume":"308","author":"A Sharma","year":"2018","unstructured":"Sharma A, Saqib M, Sheikh JA, Ehtesham NZ, Bhaskar S, Chaudhuri TK, et al. Mycobacterium indicus pranii protein MIP_05962 induces Th1 cell mediated immune response in mice. Int J Med Microbiol. 2018;308(8):1000\u20138. https:\/\/doi.org\/10.1016\/j.ijmm.2018.08.008.","journal-title":"Int J Med Microbiol"},{"issue":"3","key":"243_CR181","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1189\/jlb.1A0714-361R","volume":"97","author":"P Kumar","year":"2015","unstructured":"Kumar P, John V, Marathe S, Das G, Bhaskar S. Mycobacterium indicus pranii induces dendritic cell activation, survival, and Th1\/Th17 polarization potential in a TLR-dependent manner. J Leukoc Biol. 2015;97(3):511\u201320. https:\/\/doi.org\/10.1189\/jlb.1A0714-361R.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"243_CR182","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1128\/iai.00526-08","volume":"77","author":"A Gupta","year":"2009","unstructured":"Gupta A, Geetha N, Mani J, Upadhyay P, Katoch VM, Natrajan M, et al. Immunogenicity and protective efficacy of \u201cMycobacterium w\u201d against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route. Infect Immunity. 2009;77(1):223\u201331. https:\/\/doi.org\/10.1128\/iai.00526-08.","journal-title":"Infect Immunity."},{"key":"243_CR183","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.tube.2016.10.002","volume":"101","author":"M Saqib","year":"2016","unstructured":"Saqib M, Khatri R, Singh B, Gupta A, Kumar A, Bhaskar S. Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis. Tuberculosis (Edinb). 2016;101:164\u201373. https:\/\/doi.org\/10.1016\/j.tube.2016.10.002.","journal-title":"Tuberculosis (Edinb)"},{"issue":"7","key":"243_CR184","doi-asserted-by":"publisher","first-page":"e39215","DOI":"10.1371\/journal.pone.0039215","volume":"7","author":"A Gupta","year":"2012","unstructured":"Gupta A, Ahmad FJ, Ahmad F, Gupta UD, Natarajan M, Katoch V, et al. Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One. 2012;7(7):e39215. https:\/\/doi.org\/10.1371\/journal.pone.0039215.","journal-title":"PLoS One"},{"issue":"9","key":"243_CR185","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.vaccine.2007.12.025","volume":"26","author":"K Katoch","year":"2008","unstructured":"Katoch K, Singh P, Adhikari T, Benara SK, Singh HB, Chauhan DS, et al. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Vaccine. 2008;26(9):1228\u201334. https:\/\/doi.org\/10.1016\/j.vaccine.2007.12.025.","journal-title":"Vaccine"},{"issue":"16","key":"243_CR186","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1097\/00002030-200311070-00010","volume":"17","author":"JM Vuola","year":"2003","unstructured":"Vuola JM, Ristola MA, Cole B, J\u00e4rviluoma A, Tvaroha S, R\u00f6nkk\u00f6 T, et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS. 2003;17(16):2351\u20135. https:\/\/doi.org\/10.1097\/00002030-200311070-00010.","journal-title":"AIDS"},{"issue":"48","key":"243_CR187","doi-asserted-by":"publisher","first-page":"7652","DOI":"10.1016\/j.vaccine.2010.09.041","volume":"28","author":"T Lahey","year":"2010","unstructured":"Lahey T, Arbeit RD, Bakari M, Horsburgh CR, Matee M, Waddell R, et al. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine. 2010;28(48):7652\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2010.09.041.","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"243_CR188","doi-asserted-by":"publisher","first-page":"S309","DOI":"10.1086\/313880","volume":"30","author":"RD Waddell","year":"2000","unstructured":"Waddell RD, Chintu C, Lein AD, Zumla A, Karagas MR, Baboo KS, et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis. 2000;30(Suppl 3):S309\u201315. https:\/\/doi.org\/10.1086\/313880.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"243_CR189","doi-asserted-by":"publisher","first-page":"e0168521","DOI":"10.1371\/journal.pone.0168521","volume":"11","author":"T Lahey","year":"2016","unstructured":"Lahey T, Laddy D, Hill K, Schaeffer J, Hogg A, Keeble J, et al. Immunogenicity and protective efficacy of the DAR-901 booster vaccine in a murine model of tuberculosis. PLoS One. 2016;11(12):e0168521. https:\/\/doi.org\/10.1371\/journal.pone.0168521.","journal-title":"PLoS One"},{"issue":"5","key":"243_CR190","doi-asserted-by":"publisher","first-page":"e0175215","DOI":"10.1371\/journal.pone.0175215","volume":"12","author":"CF von Reyn","year":"2017","unstructured":"von Reyn CF, Lahey T, Arbeit RD, Landry B, Kailani L, Adams LV, et al. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901. PLoS One. 2017;12(5):e0175215. https:\/\/doi.org\/10.1371\/journal.pone.0175215.","journal-title":"PLoS One"},{"issue":"5","key":"243_CR191","doi-asserted-by":"publisher","first-page":"e0217091","DOI":"10.1371\/journal.pone.0217091","volume":"14","author":"T Masonou","year":"2019","unstructured":"Masonou T, Hokey DA, Lahey T, Halliday A, Berrocal-Almanza LC, Wieland-Alter WF, et al. CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: a randomized, placebo-controlled trial. PLoS One. 2019;14(5):e0217091. https:\/\/doi.org\/10.1371\/journal.pone.0217091.","journal-title":"PLoS One"},{"issue":"2","key":"243_CR192","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5114\/ceji.2017.69362","volume":"42","author":"MM Usman","year":"2017","unstructured":"Usman MM, Ismail S, Teoh TC. Vaccine research and development: tuberculosis as a global health threat. Cent Eur J Immunol. 2017;42(2):196\u2013204. https:\/\/doi.org\/10.5114\/ceji.2017.69362.","journal-title":"Cent Eur J Immunol"},{"issue":"3\u20134","key":"243_CR193","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.tube.2006.01.024","volume":"86","author":"PJ Cardona","year":"2006","unstructured":"Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb). 2006;86(3\u20134):273\u201389. https:\/\/doi.org\/10.1016\/j.tube.2006.01.024.","journal-title":"Tuberculosis (Edinb)"},{"issue":"8","key":"243_CR194","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1128\/cvi.00094-08","volume":"15","author":"E Guirado","year":"2008","unstructured":"Guirado E, Gil O, C\u00e1ceres N, Singh M, Vilaplana C, Cardona PJ. Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis. Clin Vaccine Immunol. 2008;15(8):1229\u201337. https:\/\/doi.org\/10.1128\/cvi.00094-08.","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"243_CR195","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.vaccine.2009.09.134","volume":"28","author":"C Vilaplana","year":"2010","unstructured":"Vilaplana C, Montan\u00e9 E, Pinto S, Barriocanal AM, Domenech G, Torres F, et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine. 2010;28(4):1106\u201316. https:\/\/doi.org\/10.1016\/j.vaccine.2009.09.134.","journal-title":"Vaccine"},{"issue":"2","key":"243_CR196","doi-asserted-by":"publisher","first-page":"e89612","DOI":"10.1371\/journal.pone.0089612","volume":"9","author":"AS Nell","year":"2014","unstructured":"Nell AS, D\u2019Lom E, Bouic P, Sabat\u00e9 M, Bosser R, Picas J, et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One. 2014;9(2):e89612. https:\/\/doi.org\/10.1371\/journal.pone.0089612.","journal-title":"PLoS One"},{"issue":"1","key":"243_CR197","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40779-020-00258-4","volume":"7","author":"WP Gong","year":"2020","unstructured":"Gong WP, Liang Y, Ling YB, Zhang JX, Yang YR, Wang L, et al. Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes. Mil Med Res. 2020;7(1):25. https:\/\/doi.org\/10.1186\/s40779-020-00258-4.","journal-title":"Mil Med Res"},{"issue":"11","key":"243_CR198","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1128\/iai.65.11.4525-4530.1997","volume":"65","author":"MA Skinner","year":"1997","unstructured":"Skinner MA, Yuan S, Prestidge R, Chuk D, Watson JD, Tan PL. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun. 1997;65(11):4525\u201330.","journal-title":"Infect Immun"},{"key":"243_CR199","unstructured":"WHO. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. p. 1-262."},{"issue":"7","key":"243_CR200","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1080\/21645515.2018.1458806","volume":"14","author":"W Gong","year":"2018","unstructured":"Gong W, Liang Y, Wu X. The current status, challenges, and future developments of new tuberculosis vaccines. Hum Vacc Immunother. 2018;14(7):1697\u2013716. https:\/\/doi.org\/10.1080\/21645515.2018.1458806.","journal-title":"Hum Vacc Immunother"},{"key":"243_CR201","doi-asserted-by":"publisher","unstructured":"Flores-Valdez MA, Kupz A, Subbian S. Recent Developments in Mycobacteria-Based Live Attenuated Vaccine Candidates for Tuberculosis. Biomedicines. 2022;10(11). https:\/\/doi.org\/10.3390\/biomedicines10112749.","DOI":"10.3390\/biomedicines10112749"},{"issue":"7","key":"243_CR202","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.3390\/app10072632","volume":"10","author":"C Mart\u00edn","year":"2020","unstructured":"Mart\u00edn C, Aguil\u00f3 N, Marinova D, Gonzalo-Asensio J. Update on TB vaccine pipeline. Appl Sci. 2020;10(7):2632.","journal-title":"Appl Sci"},{"issue":"12","key":"243_CR203","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.arbres.2023.09.009","volume":"59","author":"S Lac\u00e1mara","year":"2023","unstructured":"Lac\u00e1mara S, Martin C. MTBVAC: a tuberculosis vaccine candidate advancing towards clinical efficacy trials in TB prevention. Arch Bronconeumol. 2023;59(12):821\u20138. https:\/\/doi.org\/10.1016\/j.arbres.2023.09.009.","journal-title":"Arch Bronconeumol"},{"issue":"4","key":"243_CR204","doi-asserted-by":"publisher","first-page":"e1008404","DOI":"10.1371\/journal.ppat.1008404","volume":"16","author":"R Taranc\u00f3n","year":"2020","unstructured":"Taranc\u00f3n R, Dom\u00ednguez-Andr\u00e9s J, Uranga S, Ferreira AV, Groh LA, Domenech M, et al. New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. PLoS Pathog. 2020;16(4):e1008404. https:\/\/doi.org\/10.1371\/journal.ppat.1008404.","journal-title":"PLoS Pathog"},{"issue":"1","key":"243_CR205","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41541-020-00262-8","volume":"6","author":"AD White","year":"2021","unstructured":"White AD, Sibley L, Sarfas C, Morrison A, Gullick J, Clark S, et al. MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies. NPJ Vaccines. 2021;6(1):4. https:\/\/doi.org\/10.1038\/s41541-020-00262-8.","journal-title":"NPJ Vaccines."},{"issue":"12","key":"243_CR206","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/s2213-2600(15)00435-x","volume":"3","author":"F Spertini","year":"2015","unstructured":"Spertini F, Audran R, Chakour R, Karoui O, Steiner-Monard V, Thierry AC, et al. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med. 2015;3(12):953\u201362. https:\/\/doi.org\/10.1016\/s2213-2600(15)00435-x.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"243_CR207","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S2213-2600(19)30251-6","volume":"7","author":"M Tameris","year":"2019","unstructured":"Tameris M, Mearns H, Penn-Nicholson A, Gregg Y, Bilek N, Mabwe S, et al. Live-attenuated <em>Mycobacterium tuberculosis<\/em> vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respir Med. 2019;7(9):757\u201370. https:\/\/doi.org\/10.1016\/S2213-2600(19)30251-6.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"243_CR208","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","volume":"58","author":"P Mangtani","year":"2014","unstructured":"Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470\u201380. https:\/\/doi.org\/10.1093\/cid\/cit790.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"243_CR209","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(21)00403-5","volume":"22","author":"C Lange","year":"2022","unstructured":"Lange C, Aaby P, Behr MA, Donald PR, Kaufmann SHE, Netea MG, et al. 100 years of mycobacterium bovis bacille calmette-guerin. Lancet Infect Dis. 2022;22(1):e2\u201312. https:\/\/doi.org\/10.1016\/S1473-3099(21)00403-5.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"243_CR210","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1038\/s41467-024-49050-1","volume":"15","author":"OB Dintwe","year":"2024","unstructured":"Dintwe OB, Ballweber Fleming L, Voillet V, McNevin J, Seese A, Naidoo A, et al. Adolescent BCG revaccination induces a phenotypic shift in CD4(+) T cell responses to Mycobacterium tuberculosis. Nat Commun. 2024;15(1):5191. https:\/\/doi.org\/10.1038\/s41467-024-49050-1.","journal-title":"Nat Commun"},{"issue":"3","key":"243_CR211","doi-asserted-by":"publisher","first-page":"e56643","DOI":"10.7759\/cureus.56643","volume":"16","author":"A Lawrence","year":"2024","unstructured":"Lawrence A. Bacillus Calmette-Gu\u00e9rin (BCG) revaccination and protection against tuberculosis: a systematic review. Cureus. 2024;16(3):e56643. https:\/\/doi.org\/10.7759\/cureus.56643.","journal-title":"Cureus"},{"key":"243_CR212","doi-asserted-by":"publisher","first-page":"100313","DOI":"10.1016\/j.eclinm.2020.100313","volume":"21","author":"LG Bekker","year":"2020","unstructured":"Bekker LG, Dintwe O, Fiore-Gartland A, Middelkoop K, Hutter J, Williams A, et al. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. EClinicalMedicine. 2020;21:100313. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100313.","journal-title":"EClinicalMedicine"},{"issue":"30","key":"243_CR213","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1016\/S0264-410X(01)00155-4","volume":"19","author":"N Ohara","year":"2001","unstructured":"Ohara N, Yamada T. Recombinant BCG vaccines. Vaccine. 2001;19(30):4089\u201398.","journal-title":"Vaccine"},{"key":"243_CR214","doi-asserted-by":"publisher","unstructured":"Flores-Valdez MA. After 100 Years of BCG Immunization against Tuberculosis, What Is New and Still Outstanding for This Vaccine? Vaccines (Basel). 2021;10(1). https:\/\/doi.org\/10.3390\/vaccines10010057.","DOI":"10.3390\/vaccines10010057"},{"issue":"9","key":"243_CR215","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1172\/jci24617","volume":"115","author":"L Grode","year":"2005","unstructured":"Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Gu\u00e9rin mutants that secrete listeriolysin. J Clin Invest. 2005;115(9):2472\u20139. https:\/\/doi.org\/10.1172\/jci24617.","journal-title":"J Clin Invest"},{"key":"243_CR216","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fimmu.2020.00316","volume":"11","author":"SHE Kaufmann","year":"2020","unstructured":"Kaufmann SHE. Vaccination against tuberculosis: revamping BCG by molecular genetics guided by immunology. Front Immunol. 2020;11:316. https:\/\/doi.org\/10.3389\/fimmu.2020.00316.","journal-title":"Front Immunol"},{"issue":"9","key":"243_CR217","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1073\/pnas.95.9.5299","volume":"95","author":"J Hess","year":"1998","unstructured":"Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SH. Mycobacterium bovis Bacille Calmette-Gu\u00e9rin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA. 1998;95(9):5299\u2013304. https:\/\/doi.org\/10.1073\/pnas.95.9.5299.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"243_CR218","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/vaccines1020120","volume":"1","author":"K Velmurugan","year":"2013","unstructured":"Velmurugan K, Grode L, Chang R, Fitzpatrick M, Laddy D, Hokey D, et al. Nonclinical development of BCG replacement vaccine candidates. Vaccines (Basel). 2013;1(2):120\u201338. https:\/\/doi.org\/10.3390\/vaccines1020120.","journal-title":"Vaccines (Basel)"},{"issue":"52","key":"243_CR219","doi-asserted-by":"publisher","first-page":"7608","DOI":"10.1016\/j.vaccine.2012.10.031","volume":"30","author":"M Farinacci","year":"2012","unstructured":"Farinacci M, Weber S, Kaufmann SH. The recombinant tuberculosis vaccine rBCG \u0394ureC::hly(+) induces apoptotic vesicles for improved priming of CD4(+) and CD8(+) T cells. Vaccine. 2012;30(52):7608\u201314. https:\/\/doi.org\/10.1016\/j.vaccine.2012.10.031.","journal-title":"Vaccine"},{"key":"243_CR220","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","volume":"8","author":"NE Nieuwenhuizen","year":"2017","unstructured":"Nieuwenhuizen NE, Kulkarni PS, Shaligram U, Cotton MF, Rentsch CA, Eisele B, et al. The recombinant bacille calmette-guerin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol. 2017;8:1147. https:\/\/doi.org\/10.3389\/fimmu.2017.01147.","journal-title":"Front Immunol"},{"key":"243_CR221","doi-asserted-by":"publisher","unstructured":"Loxton AG, Knaul JK, Grode L, Gutschmidt A, Meller C, Eisele B et al. Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clin Vaccine Immunol. 2017;24(2). https:\/\/doi.org\/10.1128\/cvi.00439-16.","DOI":"10.1128\/cvi.00439-16"},{"key":"243_CR222","doi-asserted-by":"publisher","first-page":"583077","DOI":"10.3389\/fimmu.2020.583077","volume":"11","author":"M Brisse","year":"2020","unstructured":"Brisse M, Vrba SM, Kirk N, Liang Y, Ly H. Emerging concepts and technologies in vaccine development. Front Immunol. 2020;11:583077. https:\/\/doi.org\/10.3389\/fimmu.2020.583077.","journal-title":"Front Immunol"},{"key":"243_CR223","doi-asserted-by":"publisher","unstructured":"Bellini C, Horv\u00e1ti K. Recent advances in the development of protein- and peptide-based subunit vaccines against tuberculosis. Cells. 2020;9(12). https:\/\/doi.org\/10.3390\/cells9122673.","DOI":"10.3390\/cells9122673"},{"issue":"6","key":"243_CR224","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1002\/iid3.867","volume":"11","author":"M Moradi","year":"2023","unstructured":"Moradi M, Vahedi F, Abbassioun A, Ramezanpour Shahi A, Sholeh M, Taheri-Anganeh M, et al. Liposomal delivery system\/adjuvant for tuberculosis vaccine. Immun Inflamm Dis. 2023;11(6):e867. https:\/\/doi.org\/10.1002\/iid3.867.","journal-title":"Immun Inflamm Dis"},{"issue":"17","key":"243_CR225","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","volume":"379","author":"O Van Der Meeren","year":"2018","unstructured":"Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, et al. Phase 2b controlled trial of M72\/AS01(E) vaccine to prevent tuberculosis. N Engl J Med. 2018;379(17):1621\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1803484.","journal-title":"N Engl J Med"},{"issue":"1","key":"243_CR226","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2249.2004.02609.x","volume":"138","author":"R Al-Attiyah","year":"2004","unstructured":"Al-Attiyah R, Mustafa AS, Abal AT, El-Shamy AS, Dalemans W, Skeiky YA. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol. 2004;138(1):139\u201344. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02609.x.","journal-title":"Clin Exp Immunol"},{"issue":"32","key":"243_CR227","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","volume":"33","author":"A Penn-Nicholson","year":"2015","unstructured":"Penn-Nicholson A, Geldenhuys H, Burny W, van der Most R, Day CL, Jongert E, et al. Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting. Vaccine. 2015;33(32):4025\u201334. https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.088.","journal-title":"Vaccine"},{"issue":"25","key":"243_CR228","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","volume":"381","author":"DR Tait","year":"2019","unstructured":"Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, et al. Final analysis of a trial of M72\/AS01(E) vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1909953.","journal-title":"N Engl J Med"},{"issue":"4","key":"243_CR229","doi-asserted-by":"publisher","first-page":"e0176784","DOI":"10.1371\/journal.pone.0176784","volume":"12","author":"AP Tkachuk","year":"2017","unstructured":"Tkachuk AP, Gushchin VA, Potapov VD, Demidenko AV, Lunin VG, Gintsburg AL. Multi-subunit BCG booster vaccine GamTBvac: assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. PLoS One. 2017;12(4):e0176784. https:\/\/doi.org\/10.1371\/journal.pone.0176784.","journal-title":"PLoS One"},{"key":"243_CR230","doi-asserted-by":"publisher","unstructured":"Tkachuk AP, Bykonia EN, Popova LI, Kleymenov DA, Semashko MA, Chulanov VP et al. Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study. Vaccines (Basel). 2020;8(4). https:\/\/doi.org\/10.3390\/vaccines8040652.","DOI":"10.3390\/vaccines8040652"},{"issue":"2","key":"243_CR231","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm.2285","volume":"17","author":"C Aagaard","year":"2011","unstructured":"Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011;17(2):189\u201394. https:\/\/doi.org\/10.1038\/nm.2285.","journal-title":"Nat Med"},{"issue":"26","key":"243_CR232","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1016\/j.vaccine.2006.03.071","volume":"24","author":"C Schellack","year":"2006","unstructured":"Schellack C, Prinz K, Egyed A, Fritz JH, Wittmann B, Ginzler M, et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine. 2006;24(26):5461\u201372. https:\/\/doi.org\/10.1016\/j.vaccine.2006.03.071.","journal-title":"Vaccine"},{"key":"243_CR233","doi-asserted-by":"publisher","unstructured":"Tait D, Diacon A, Borges \u00c1 H, van Brakel E, Hokey D, Rutkowski KT et al. Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial. J Infect Dis. 2024. https:\/\/doi.org\/10.1093\/infdis\/jiae170.","DOI":"10.1093\/infdis\/jiae170"},{"key":"243_CR234","doi-asserted-by":"publisher","unstructured":"Li F, Dang W, Du Y, Xu X, He P, Zhou Y et al. Tuberculosis Vaccines and T Cell Immune Memory. Vaccines (Basel). 2024;12(5). https:\/\/doi.org\/10.3390\/vaccines12050483.","DOI":"10.3390\/vaccines12050483"},{"issue":"30","key":"243_CR235","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1016\/j.vaccine.2015.05.036","volume":"33","author":"H Geldenhuys","year":"2015","unstructured":"Geldenhuys H, Mearns H, Miles DJ, Tameris M, Hokey D, Shi Z, et al. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial. Vaccine. 2015;33(30):3592\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.036.","journal-title":"Vaccine"},{"issue":"12","key":"243_CR236","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.vaccine.2017.01.055","volume":"35","author":"M Norrby","year":"2017","unstructured":"Norrby M, Vesikari T, Lindqvist L, Maeurer M, Ahmed R, Mahdavifar S, et al. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: two phase I dose escalation trials. Vaccine. 2017;35(12):1652\u201361. https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.055.","journal-title":"Vaccine"},{"issue":"2","key":"243_CR237","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1128\/CVI.00458-15","volume":"23","author":"SL Baldwin","year":"2016","unstructured":"Baldwin SL, Reese VA, Huang PW, Beebe EA, Podell BK, Reed SG, et al. Protection and long-lived immunity induced by the ID93\/GLA-SE vaccine candidate against a clinical mycobacterium tuberculosis Isolate. Clin Vaccine Immunol. 2016;23(2):137\u201347. https:\/\/doi.org\/10.1128\/CVI.00458-15.","journal-title":"Clin Vaccine Immunol"},{"key":"243_CR238","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41541-018-0057-5","volume":"3","author":"RN Coler","year":"2018","unstructured":"Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, et al. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines. 2018;3:34. https:\/\/doi.org\/10.1038\/s41541-018-0057-5.","journal-title":"NPJ Vaccines"},{"issue":"4","key":"243_CR239","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/s2213-2600(18)30077-8","volume":"6","author":"A Penn-Nicholson","year":"2018","unstructured":"Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, et al. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med. 2018;6(4):287\u201398. https:\/\/doi.org\/10.1016\/s2213-2600(18)30077-8.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"243_CR240","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4161\/hv.22755","volume":"9","author":"C Asokanathan","year":"2013","unstructured":"Asokanathan C, Corbel M, Xing D. A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis. Hum Vaccin Immunother. 2013;9(2):325\u201331. https:\/\/doi.org\/10.4161\/hv.22755.","journal-title":"Hum Vaccin Immunother"},{"issue":"17","key":"243_CR241","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/s0264-410x(99)00526-5","volume":"18","author":"RD Weeratna","year":"2000","unstructured":"Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 2000;18(17):1755\u201362. https:\/\/doi.org\/10.1016\/s0264-410x(99)00526-5.","journal-title":"Vaccine"},{"issue":"9","key":"243_CR242","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41577-019-0174-z","volume":"19","author":"P Andersen","year":"2019","unstructured":"Andersen P, Scriba TJ. Moving tuberculosis vaccines from theory to practice. Nat Rev Immunol. 2019;19(9):550\u201362. https:\/\/doi.org\/10.1038\/s41577-019-0174-z.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"243_CR243","doi-asserted-by":"publisher","first-page":"e26193","DOI":"10.1016\/j.heliyon.2024.e26193","volume":"10","author":"R Hoseinpour","year":"2024","unstructured":"Hoseinpour R, Hasani A, Baradaran B, Abdolalizadeh J, Salehi R, Hasani A, et al. Tuberculosis vaccine developments and efficient delivery systems: a comprehensive appraisal. Heliyon. 2024;10(4):e26193. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26193.","journal-title":"Heliyon"},{"issue":"4","key":"243_CR244","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1086\/590185","volume":"198","author":"T Hawkridge","year":"2008","unstructured":"Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis. 2008;198(4):544\u201352. https:\/\/doi.org\/10.1086\/590185.","journal-title":"J Infect Dis"},{"issue":"12","key":"243_CR245","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/infdis\/jir195","volume":"203","author":"TJ Scriba","year":"2011","unstructured":"Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Mauff K, et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis. 2011;203(12):1832\u201343. https:\/\/doi.org\/10.1093\/infdis\/jir195.","journal-title":"J Infect Dis"},{"issue":"4","key":"243_CR246","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/cid\/cix834","volume":"66","author":"E Nemes","year":"2018","unstructured":"Nemes E, Hesseling AC, Tameris M, Mauff K, Downing K, Mulenga H, et al. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: a Phase 2 Randomized, Controlled Trial. Clin Infect Dis. 2018;66(4):554\u201363. https:\/\/doi.org\/10.1093\/cid\/cix834.","journal-title":"Clin Infect Dis"},{"issue":"48","key":"243_CR247","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","volume":"33","author":"E Stylianou","year":"2015","unstructured":"Stylianou E, Griffiths KL, Poyntz HC, Harrington-Kandt R, Dicks MD, Stockdale L, et al. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. Vaccine. 2015;33(48):6800\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.017.","journal-title":"Vaccine"},{"issue":"9","key":"243_CR248","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.vaccine.2021.01.034","volume":"39","author":"N Pinpathomrat","year":"2021","unstructured":"Pinpathomrat N, Bull N, Pasricha J, Harrington-Kandt R, McShane H, Stylianou E. Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model. Vaccine. 2021;39(9):1452\u201362. https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.034.","journal-title":"Vaccine"},{"issue":"4","key":"243_CR249","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.vaccine.2019.10.102","volume":"38","author":"M Wilkie","year":"2020","unstructured":"Wilkie M, Satti I, Minhinnick A, Harris S, Riste M, Ramon RL, et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults. Vaccine. 2020;38(4):779\u201389. https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.102.","journal-title":"Vaccine"},{"issue":"8","key":"243_CR250","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1586\/14760584.2014.929947","volume":"13","author":"F Smaill","year":"2014","unstructured":"Smaill F, Xing Z. Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future? Expert Rev Vaccines. 2014;13(8):927\u201330. https:\/\/doi.org\/10.1586\/14760584.2014.929947.","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"243_CR251","doi-asserted-by":"publisher","first-page":"6357","DOI":"10.4049\/jimmunol.173.10.6357","volume":"173","author":"J Wang","year":"2004","unstructured":"Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol (Baltimore, Md\u202f: 1950). 2004;173(10):6357\u201365. https:\/\/doi.org\/10.4049\/jimmunol.173.10.6357.","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"205","key":"243_CR252","doi-asserted-by":"publisher","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","volume":"5","author":"F Smaill","year":"2013","unstructured":"Smaill F, Jeyanathan M, Smieja M, Medina MF, Thanthrige-Don N, Zganiacz A, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med. 2013;5(205):205ra134. https:\/\/doi.org\/10.1126\/scitranslmed.3006843.","journal-title":"Sci Transl Med."},{"key":"243_CR253","doi-asserted-by":"publisher","unstructured":"Srivastava S, Dey S, Mukhopadhyay S. Vaccines against Tuberculosis: Where Are We Now? Vaccines (Basel). 2023;11(5). https:\/\/doi.org\/10.3390\/vaccines11051013.","DOI":"10.3390\/vaccines11051013"},{"key":"243_CR254","doi-asserted-by":"publisher","unstructured":"Shurygina AP, Zabolotnykh N, Vinogradova T, Khairullin B, Kassenov M, Nurpeisova A et al. Preclinical Evaluation of TB\/FLU-04L-An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis. Int J Mol Sci. 2023;24(8). https:\/\/doi.org\/10.3390\/ijms24087439.","DOI":"10.3390\/ijms24087439"},{"issue":"5","key":"243_CR255","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1055\/a-1785-3936","volume":"72","author":"Z Buzitskaya","year":"2022","unstructured":"Buzitskaya Z, Stosman K, Khairullin B, Kassenov M, Nurpeisova A, Abylai Sansyzbay A, et al. A new intranasal influenza vector-based vaccine TB\/FLU-04L against tuberculosis: preclinical safety studies. Drug Res. 2022;72(5):255\u20138. https:\/\/doi.org\/10.1055\/a-1785-3936.","journal-title":"Drug Res"},{"issue":"4","key":"243_CR256","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/a-1771-5985","volume":"72","author":"K Stosman","year":"2022","unstructured":"Stosman K, Sivak K, Aleksandrov A, Buzitskaya Z, Rassokha T, Stukova M. Preclinical safety evaluation: acute and repeated-dose toxicity of a new intranasal recombinant vector vaccine TB\/FLU-04L against tuberculosis. Drug research. 2022;72(4):215\u20139. https:\/\/doi.org\/10.1055\/a-1771-5985.","journal-title":"Drug research"},{"issue":"3","key":"243_CR257","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.cellin.2022.100029","volume":"1","author":"Y Chen","year":"2022","unstructured":"Chen Y, Liu Q, Zhou L, Zhou Y, Yan H, Lan K. Emerging SARS-CoV-2 variants: Why, how, and what\u2019s next? Cell Insight. 2022;1(3):100029. https:\/\/doi.org\/10.1016\/j.cellin.2022.100029.","journal-title":"Cell Insight"},{"issue":"12","key":"243_CR258","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.molmed.2013.09.002","volume":"19","author":"C Pollard","year":"2013","unstructured":"Pollard C, De Koker S, Saelens X, Vanham G, Grooten J. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med. 2013;19(12):705\u201313. https:\/\/doi.org\/10.1016\/j.molmed.2013.09.002.","journal-title":"Trends Mol Med"},{"issue":"3","key":"243_CR259","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2020","unstructured":"Linares-Fern\u00e1ndez S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA Vaccine to Balance Innate\/Adaptive Immune Response. Trends Mol Med. 2020;26(3):311\u201323. https:\/\/doi.org\/10.1016\/j.molmed.2019.10.002.","journal-title":"Trends Mol Med"},{"issue":"1","key":"243_CR260","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41541-024-00834-y","volume":"9","author":"S Chugh","year":"2024","unstructured":"Chugh S, Bahal RK, Dhiman R, Singh R. Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development. NPJ vaccines. 2024;9(1):57. https:\/\/doi.org\/10.1038\/s41541-024-00834-y.","journal-title":"NPJ vaccines"},{"issue":"1","key":"243_CR261","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1038\/ncomms4369","volume":"5","author":"A Koul","year":"2014","unstructured":"Koul A, Vranckx L, Dhar N, G\u00f6hlmann HWH, \u00d6zdemir E, Neefs J-M, et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun. 2014;5(1):3369. https:\/\/doi.org\/10.1038\/ncomms4369.","journal-title":"Nat Commun"},{"key":"243_CR262","unstructured":"Centers for Disease Control and Prevention. Treatment Regimens for Latent TB Infection. https:\/\/www.cdcgov\/tb\/topic\/treatment\/ltbihtm. 2020."},{"issue":"2","key":"243_CR263","doi-asserted-by":"publisher","first-page":"e0281638","DOI":"10.1371\/journal.pone.0281638","volume":"18","author":"JP Cola","year":"2023","unstructured":"Cola JP, Prado TND, Campos BA, Borges BJP, Alves B, Jezus SV, et al. Protocol for pragmatic randomized clinical trial to evaluate the completion of treatment of latent Mycobacterium tuberculosis infection with Isoniazid in the 300 mg formulation. PLoS One. 2023;18(2):e0281638. https:\/\/doi.org\/10.1371\/journal.pone.0281638.","journal-title":"PLoS One"},{"key":"243_CR264","doi-asserted-by":"publisher","unstructured":"Xu AY, Vel\u00e1squez GE, Zhang N, Chang VK, Phillips PP, Nahid P et al. Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial. American journal of respiratory and critical care medicine. 2024. https:\/\/doi.org\/10.1164\/rccm.202401-0165OC.","DOI":"10.1164\/rccm.202401-0165OC"},{"issue":"1","key":"243_CR265","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1473-3099(18)30480-8","volume":"19","author":"J-K Lee","year":"2019","unstructured":"Lee J-K, Lee JY, Kim DK, Yoon HI, Jeong I, Heo EY, et al. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. Lancet Infect Dis. 2019;19(1):46\u201355. https:\/\/doi.org\/10.1016\/S1473-3099(18)30480-8.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"243_CR266","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","volume":"10","author":"JA Caminero","year":"2010","unstructured":"Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621\u20139. https:\/\/doi.org\/10.1016\/S1473-3099(10)70139-0.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"243_CR267","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1164\/rccm.201303-0604OC","volume":"188","author":"WJ Koh","year":"2013","unstructured":"Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013;188(7):858\u201364. https:\/\/doi.org\/10.1164\/rccm.201303-0604OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"243_CR268","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","volume":"17","author":"MJ Boeree","year":"2017","unstructured":"Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39\u201349. https:\/\/doi.org\/10.1016\/S1473-3099(16)30274-2.","journal-title":"Lancet Infect Dis"},{"key":"243_CR269","doi-asserted-by":"publisher","unstructured":"Espinosa-Pereiro J, Ghimire S, Sturkenboom MGG, Alffenaar JC, Tavares M, Aguirre S et al. Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b\/c Trial. Pharmaceutics. 2022;15(1). https:\/\/doi.org\/10.3390\/pharmaceutics15010009.","DOI":"10.3390\/pharmaceutics15010009"},{"issue":"7","key":"243_CR270","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.3390\/app10072211","volume":"10","author":"YL Cho","year":"2020","unstructured":"Cho YL, Jang J. Development of delpazolid for the treatment of tuberculosis. Appl Sci. 2020;10(7):2211.","journal-title":"Appl Sci"},{"issue":"4","key":"243_CR271","doi-asserted-by":"publisher","first-page":"e94462","DOI":"10.1371\/journal.pone.0094462","volume":"9","author":"RS Wallis","year":"2014","unstructured":"Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One. 2014;9(4):e94462. https:\/\/doi.org\/10.1371\/journal.pone.0094462.","journal-title":"PLoS One"},{"key":"243_CR272","doi-asserted-by":"crossref","unstructured":"Strydom N, Ernest JP, Imperial M, et al. Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen. Nat Commun. 2024;15(1):7311.","DOI":"10.1038\/s41467-024-50781-4"},{"issue":"23","key":"243_CR273","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","volume":"366","author":"MT Gler","year":"2012","unstructured":"Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1112433.","journal-title":"N Engl J Med"},{"issue":"16","key":"243_CR274","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam SJ. Pretomanid: first approval. Drugs. 2019;79(16):1797\u2013803. https:\/\/doi.org\/10.1007\/s40265-019-01207-9.","journal-title":"Drugs"},{"issue":"2","key":"243_CR275","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1183\/13993003.00724-2015","volume":"47","author":"AS Pym","year":"2016","unstructured":"Pym AS, Diacon AH, Tang S-J, Conradie F, Danilovits M, Chuchottaworn C, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564\u201374. https:\/\/doi.org\/10.1183\/13993003.00724-2015.","journal-title":"Eur Respir J"},{"issue":"8","key":"243_CR276","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.bmc.2018.02.026","volume":"26","author":"HS Sutherland","year":"2018","unstructured":"Sutherland HS, Tong AST, Choi PJ, Conole D, Blaser A, Franzblau SG, et al. Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles. Bioorg Med Chem. 2018;26(8):1797\u2013809. https:\/\/doi.org\/10.1016\/j.bmc.2018.02.026.","journal-title":"Bioorg Med Chem"},{"key":"243_CR277","doi-asserted-by":"publisher","unstructured":"Sarathy Jickky P, Ganapathy Uday S, Zimmerman Matthew D, Dartois V, Gengenbacher M, Dick T. TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. Antimicrob Agents Chemother. 2020;64(4). https:\/\/doi.org\/10.1128\/aac.02404-19. https:\/\/doi.org\/10.1128\/aac.02404-19.","DOI":"10.1128\/aac.02404-19 10.1128\/aac.02404-19"},{"key":"243_CR278","doi-asserted-by":"publisher","unstructured":"Sarathy Jickky P, Ragunathan P, Shin J, Cooper Christopher B, Upton Anna M, Gr\u00fcber G et al. TBAJ-876 Retains Bedaquiline\u2019s Activity against Subunits c and \u03b5 of Mycobacterium tuberculosis F-ATP Synthase. Antimicrob Agents Chemother. 2019;63(10). https:\/\/doi.org\/10.1128\/aac.01191-19. https:\/\/doi.org\/10.1128\/aac.01191-19.","DOI":"10.1128\/aac.01191-19 10.1128\/aac.01191-19"},{"key":"243_CR279","doi-asserted-by":"publisher","unstructured":"Lupien A, Vocat A, Foo Caroline S-Y, Blattes E, Gillon J-Y, Makarov V et al. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169). Antimicrob Agents Chemother. 2018;62(11). https:\/\/doi.org\/10.1128\/aac.00840-18. https:\/\/doi.org\/10.1128\/aac.00840-18.","DOI":"10.1128\/aac.00840-18 10.1128\/aac.00840-18"},{"issue":"7","key":"243_CR280","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.3390\/app10072269","volume":"10","author":"V Makarov","year":"2020","unstructured":"Makarov V, Miku\u0161ov\u00e1 K. Development of macozinone for TB treatment: an update. Appl Sci. 2020;10(7):2269.","journal-title":"Appl Sci"},{"issue":"5928","key":"243_CR281","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.1171583","volume":"324","author":"V Makarov","year":"2009","unstructured":"Makarov V, Manina G, Mikusova K, M\u00f6llmann U, Ryabova O, Saint-Joanis B, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science. 2009;324(5928):801\u20134. https:\/\/doi.org\/10.1126\/science.1171583.","journal-title":"Science"},{"issue":"1","key":"243_CR282","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40\u201351. https:\/\/doi.org\/10.1038\/nbt.2786.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"243_CR283","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1513\/AnnalsATS.201509-632PS","volume":"12","author":"JF Murray","year":"2015","unstructured":"Murray JF, Schraufnagel DE, Hopewell PC. Treatment of tuberculosis. A historical perspective. Ann Am Thorac Soc. 2015;12(12):1749\u201359. https:\/\/doi.org\/10.1513\/AnnalsATS.201509-632PS.","journal-title":"Ann Am Thorac Soc."},{"issue":"31","key":"243_CR284","doi-asserted-by":"publisher","first-page":"9582","DOI":"10.1021\/ja073160k","volume":"129","author":"A Argyrou","year":"2007","unstructured":"Argyrou A, Vetting MW, Blanchard JS. New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INH-NADP. J Am Chem Soc. 2007;129(31):9582\u20133. https:\/\/doi.org\/10.1021\/ja073160k.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"243_CR285","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1574-6968.1996.tb08515.x","volume":"144","author":"H Taniguchi","year":"1996","unstructured":"Taniguchi H, Aramaki H, Nikaido Y, Mizuguchi Y, Nakamura M, Koga T, et al. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett. 1996;144(1):103\u20138. https:\/\/doi.org\/10.1111\/j.1574-6968.1996.tb08515.x.","journal-title":"FEMS Microbiol Lett"},{"issue":"10","key":"243_CR286","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1128\/aac.00162-09","volume":"53","author":"R Goude","year":"2009","unstructured":"Goude R, Amin AG, Chatterjee D, Parish T. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009;53(10):4138\u201346. https:\/\/doi.org\/10.1128\/aac.00162-09.","journal-title":"Antimicrob Agents Chemother"},{"key":"243_CR287","doi-asserted-by":"crossref","unstructured":"Santucci P, Greenwood DJ, Fearns A, Chen K, Jiang H, Gutierrez MG. Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide. Nat Commun. 2021;12(1):3816.","DOI":"10.1038\/s41467-021-24127-3"},{"issue":"5","key":"243_CR288","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/jac\/dkg446","volume":"52","author":"Y Zhang","year":"2003","unstructured":"Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother. 2003;52(5):790\u20135. https:\/\/doi.org\/10.1093\/jac\/dkg446.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"243_CR289","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nm0696-662","volume":"2","author":"A Scorpio","year":"1996","unstructured":"Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med. 1996;2(6):662\u20137. https:\/\/doi.org\/10.1038\/nm0696-662.","journal-title":"Nat Med"},{"issue":"9","key":"243_CR290","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2217\/fmb.13.85","volume":"8","author":"JC Palomino","year":"2013","unstructured":"Palomino JC, Martin A. TMC207 becomes Bedaquiline, a new anti-TB drug. Future Microbiol. 2013;8(9):1071\u201380. https:\/\/doi.org\/10.2217\/fmb.13.85.","journal-title":"Future Microbiol"},{"issue":"4","key":"243_CR291","doi-asserted-by":"publisher","first-page":"e1500106","DOI":"10.1126\/sciadv.1500106","volume":"1","author":"L Preiss","year":"2015","unstructured":"Preiss L, Langer JD, Yildiz \u00d6, Eckhardt-Strelau L, Guillemont JE, Koul A, et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv. 2015;1(4):e1500106. https:\/\/doi.org\/10.1126\/sciadv.1500106.","journal-title":"Sci Adv"},{"issue":"7","key":"243_CR292","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1093\/jac\/dkv054","volume":"70","author":"K Hards","year":"2015","unstructured":"Hards K, Robson JR, Berney M, Shaw L, Bald D, Koul A, et al. Bactericidal mode of action of bedaquiline. J Antimicrob Chemother. 2015;70(7):2028\u201337. https:\/\/doi.org\/10.1093\/jac\/dkv054.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"243_CR293","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.tips.2019.10.005","volume":"40","author":"P Gopal","year":"2019","unstructured":"Gopal P, Gr\u00fcber G, Dartois V, Dick T. Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide. Trends Pharmacol Sci. 2019;40(12):930\u201340. https:\/\/doi.org\/10.1016\/j.tips.2019.10.005.","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"243_CR294","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1093\/jac\/dku171","volume":"69","author":"RPG van Heeswijk","year":"2014","unstructured":"van Heeswijk RPG, Dannemann B, Hoetelmans RMW. Bedaquiline: a review of human pharmacokinetics and drug\u2013drug interactions. J Antimicrob Chemother. 2014;69(9):2310\u20138. https:\/\/doi.org\/10.1093\/jac\/dku171.","journal-title":"J Antimicrob Chemother"},{"issue":"6789","key":"243_CR295","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/35016103","volume":"405","author":"CK Stover","year":"2000","unstructured":"Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405(6789):962\u20136. https:\/\/doi.org\/10.1038\/35016103.","journal-title":"Nature"},{"issue":"4","key":"243_CR296","doi-asserted-by":"publisher","first-page":"e00180","DOI":"10.1128\/cmr.00180-19","volume":"35","author":"N Dookie","year":"2022","unstructured":"Dookie N, Ngema Senamile L, Perumal R, Naicker N, Padayatchi N, Naidoo K. The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives. Clin Microbiol Rev. 2022;35(4):e00180-e219. https:\/\/doi.org\/10.1128\/cmr.00180-19.","journal-title":"Clin Microbiol Rev"},{"issue":"1737","key":"243_CR297","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1098\/rspb.2011.2712","volume":"279","author":"MG Gomes","year":"2012","unstructured":"Gomes MG, Aguas R, Lopes JS, Nunes MC, Rebelo C, Rodrigues P, et al. How host heterogeneity governs tuberculosis reinfection? Proc Biol Sci. 2012;279(1737):2473\u20138. https:\/\/doi.org\/10.1098\/rspb.2011.2712.","journal-title":"Proc Biol Sci"},{"issue":"3","key":"243_CR298","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/ng.2878","volume":"46","author":"N Casali","year":"2014","unstructured":"Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet. 2014;46(3):279\u201386. https:\/\/doi.org\/10.1038\/ng.2878.","journal-title":"Nat Genet"},{"key":"243_CR299","doi-asserted-by":"crossref","unstructured":"Parkkinen J, Bhowmik R, Tolvanen M, et al. Mycobacterial \u03b2-carbonic anhydrases: Molecular biology, role in the pathogenesis of tuberculosis and inhibition studies. Enzymes. 2024;55:343-81.","DOI":"10.1016\/bs.enz.2024.05.012"},{"issue":"1","key":"243_CR300","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-3156.2010.02665.x","volume":"16","author":"A Zumla","year":"2011","unstructured":"Zumla A, Atun R, Maeurer M, Mwaba P, Ma Z, O\u2019Grady J, et al. Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health. 2011;16(1):79\u201383. https:\/\/doi.org\/10.1111\/j.1365-3156.2010.02665.x.","journal-title":"Trop Med Int Health"},{"key":"243_CR301","doi-asserted-by":"publisher","first-page":"m216","DOI":"10.1136\/bmj.m216","volume":"368","author":"A Lee","year":"2020","unstructured":"Lee A, Xie YL, Barry CE, Chen RY. Current and future treatments for tuberculosis. BMJ. 2020;368:m216. https:\/\/doi.org\/10.1136\/bmj.m216.","journal-title":"BMJ"},{"issue":"2","key":"243_CR302","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","volume":"13","author":"C Young","year":"2020","unstructured":"Young C, Walzl G, Du Plessis N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol. 2020;13(2):190\u2013204. https:\/\/doi.org\/10.1038\/s41385-019-0226-5.","journal-title":"Mucosal Immunol"},{"issue":"1","key":"243_CR303","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","volume":"17","author":"SHE Kaufmann","year":"2018","unstructured":"Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discovery. 2018;17(1):35\u201356. https:\/\/doi.org\/10.1038\/nrd.2017.162.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"243_CR304","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000490478","volume":"63","author":"I Palucci","year":"2018","unstructured":"Palucci I, Delogu G. Host directed therapies for tuberculosis: futures strategies for an ancient disease. Chemotherapy. 2018;63(3):172\u201380. https:\/\/doi.org\/10.1159\/000490478.","journal-title":"Chemotherapy"},{"key":"243_CR305","doi-asserted-by":"publisher","first-page":"114588","DOI":"10.1016\/j.biopha.2023.114588","volume":"162","author":"S Ayodele","year":"2023","unstructured":"Ayodele S, Kumar P, van Eyk A, Choonara YE. Advances in immunomodulatory strategies for host-directed therapies in combating tuberculosis. Biomed Pharmacother. 2023;162:114588. https:\/\/doi.org\/10.1016\/j.biopha.2023.114588.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"243_CR306","doi-asserted-by":"publisher","first-page":"e0138340","DOI":"10.1371\/journal.pone.0138340","volume":"10","author":"A Mily","year":"2015","unstructured":"Mily A, Rekha RS, Kamal SM, Arifuzzaman AS, Rahim Z, Khan L, et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial. PLoS One. 2015;10(9):e0138340. https:\/\/doi.org\/10.1371\/journal.pone.0138340.","journal-title":"PLoS One"},{"issue":"1","key":"243_CR307","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2334-13-22","volume":"13","author":"N Salahuddin","year":"2013","unstructured":"Salahuddin N, Ali F, Hasan Z, Rao N, Aqeel M, Mahmood F. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis\u2019. BMC Infect Dis. 2013;13(1):22. https:\/\/doi.org\/10.1186\/1471-2334-13-22.","journal-title":"BMC Infect Dis."},{"issue":"5","key":"243_CR308","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3945\/ajcn.115.113886","volume":"102","author":"N Tukvadze","year":"2015","unstructured":"Tukvadze N, Sanikidze E, Kipiani M, Hebbar G, Easley KA, Shenvi N, et al. High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial12. Am J Clin Nutr. 2015;102(5):1059\u201369. https:\/\/doi.org\/10.3945\/ajcn.115.113886.","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"243_CR309","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.chom.2009.08.004","volume":"6","author":"JM Yuk","year":"2009","unstructured":"Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, et al. Vitamin D3 induces autophagy in human monocytes\/macrophages via cathelicidin. Cell Host Microbe. 2009;6(3):231\u201343. https:\/\/doi.org\/10.1016\/j.chom.2009.08.004.","journal-title":"Cell Host Microbe"},{"issue":"263","key":"243_CR310","doi-asserted-by":"publisher","first-page":"263ra159","DOI":"10.1126\/scitranslmed.3009885","volume":"6","author":"A Singhal","year":"2014","unstructured":"Singhal A, Jie L, Kumar P, Hong GS, Leow MK, Paleja B, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med. 2014;6(263):263ra159. https:\/\/doi.org\/10.1126\/scitranslmed.3009885.","journal-title":"Sci Transl Med."},{"issue":"8","key":"243_CR311","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.4049\/jimmunol.1203142","volume":"191","author":"L Wang","year":"2013","unstructured":"Wang L, Zhang L, Zhao X, Zhang M, Zhao W, Gao C. Lithium attenuates IFN-\u03b2 production and antiviral response via inhibition of TANK-binding kinase 1 kinase activity. J Immunol (Baltimore, Md\u202f: 1950). 2013;191(8):4392\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1203142.","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"6","key":"243_CR312","first-page":"3262","volume":"23","author":"SM Stepkowski","year":"1991","unstructured":"Stepkowski SM, Kahan BD. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival. Transplant Proc. 1991;23(6):3262\u20134.","journal-title":"Transplant Proc"},{"issue":"5","key":"243_CR313","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/infdis\/jit550","volume":"209","author":"SP Parihar","year":"2014","unstructured":"Parihar SP, Guler R, Khutlang R, Lang DM, Hurdayal R, Mhlanga MM, et al. Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis. 2014;209(5):754\u201363. https:\/\/doi.org\/10.1093\/infdis\/jit550.","journal-title":"J Infect Dis"},{"issue":"6","key":"243_CR314","doi-asserted-by":"publisher","first-page":"e39680","DOI":"10.1371\/journal.pone.0039680","volume":"7","author":"C Skerry","year":"2012","unstructured":"Skerry C, Harper J, Klunk M, Bishai WR, Jain SK. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS One. 2012;7(6):e39680. https:\/\/doi.org\/10.1371\/journal.pone.0039680.","journal-title":"PLoS One"},{"issue":"9","key":"243_CR315","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/14787210.2021.1892488","volume":"19","author":"VY Su","year":"2021","unstructured":"Su VY, Pan SW, Yen YF, Feng JY, Su WJ, Chen YM. Statin use and impact on tuberculosis risk. Expert Rev Anti Infect Ther. 2021;19(9):1093\u20138. https:\/\/doi.org\/10.1080\/14787210.2021.1892488.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"243_CR316","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cell.2011.12.023","volume":"148","author":"DM Tobin","year":"2012","unstructured":"Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell. 2012;148(3):434\u201346. https:\/\/doi.org\/10.1016\/j.cell.2011.12.023.","journal-title":"Cell"},{"issue":"4","key":"243_CR317","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijantimicag.2007.04.016","volume":"30","author":"NK Dutta","year":"2007","unstructured":"Dutta NK, Mazumdar K, Dastidar SG, Park JH. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice. Int J Antimicrob Agents. 2007;30(4):336\u201340. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.04.016.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"243_CR318","first-page":"124","volume":"2","author":"ML Bourigault","year":"2013","unstructured":"Bourigault ML, Vacher R, Rose S, Olleros ML, Janssens JP, Quesniaux VF, et al. Tumor necrosis factor neutralization combined with chemotherapy enhances Mycobacterium tuberculosis clearance and reduces lung pathology. Am J Clin Exp Immunol. 2013;2(1):124\u201334.","journal-title":"Am J Clin Exp Immunol"},{"issue":"6","key":"243_CR319","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1073\/pnas.1424563112","volume":"112","author":"M Datta","year":"2015","unstructured":"Datta M, Via LE, Kamoun WS, Liu C, Chen W, Seano G, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci USA. 2015;112(6):1827\u201332. https:\/\/doi.org\/10.1073\/pnas.1424563112.","journal-title":"Proc Natl Acad Sci USA"},{"key":"243_CR320","doi-asserted-by":"publisher","first-page":"100003","DOI":"10.1016\/j.dcit.2023.100003","volume":"1","author":"H Ben Ayed","year":"2023","unstructured":"Ben Ayed H, Koubaa M, Chtourou S, Rekik K, Hammami F, Marrekchi C, et al. A new scoring system to predict tuberculosis among South-Tunisian patients with lymphocytic meningitis. Decoding Infect Transm. 2023;1:100003. https:\/\/doi.org\/10.1016\/j.dcit.2023.100003.","journal-title":"Decoding Infect Transm"},{"key":"243_CR321","doi-asserted-by":"publisher","first-page":"20230138","DOI":"10.1002\/EXP.20230138","volume":"2","author":"Z Ye","year":"2024","unstructured":"Ye Z, Li L, Yang L, Zhuang L, Aspatwar A, Wang L, et al. Impact of diabetes mellitus on tuberculosis prevention, diagnosis, and treatment from an immunologic perspective. Exploration. 2024;2:20230138. https:\/\/doi.org\/10.1002\/EXP.20230138.","journal-title":"Exploration"},{"issue":"1","key":"243_CR322","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40779-023-00490-8","volume":"10","author":"LS Li","year":"2023","unstructured":"Li LS, Yang L, Zhuang L, Ye ZY, Zhao WG, Gong WP. From immunology to artificial intelligence: revolutionizing latent tuberculosis infection diagnosis with machine learning. Mil Med Res. 2023;10(1):58. https:\/\/doi.org\/10.1186\/s40779-023-00490-8.","journal-title":"Mil Med Res"},{"issue":"2","key":"243_CR323","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/sj.gene.6364051","volume":"5","author":"MJ Newport","year":"2004","unstructured":"Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist CA, Marchant A. Genetic regulation of immune responses to vaccines in early life. Genes Immun. 2004;5(2):122\u20139. https:\/\/doi.org\/10.1038\/sj.gene.6364051.","journal-title":"Genes Immun"},{"issue":"8","key":"243_CR324","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrmicro1211","volume":"3","author":"P Andersen","year":"2005","unstructured":"Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005;3(8):656\u201362. https:\/\/doi.org\/10.1038\/nrmicro1211.","journal-title":"Nat Rev Microbiol"},{"key":"243_CR325","doi-asserted-by":"publisher","unstructured":"Hosseinian K, Gerami A, Bral M, Venketaraman V. Mycobacterium tuberculosis-Human Immunodeficiency Virus Infection and the Role of T Cells in Protection. Vaccines (Basel). 2024;12(7). https:\/\/doi.org\/10.3390\/vaccines12070730.","DOI":"10.3390\/vaccines12070730"},{"issue":"3","key":"243_CR326","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/s1473-3099(19)30625-5","volume":"20","author":"LK Schrager","year":"2020","unstructured":"Schrager LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF. The status of tuberculosis vaccine development. Lancet Infect Dis. 2020;20(3):e28\u201337. https:\/\/doi.org\/10.1016\/s1473-3099(19)30625-5.","journal-title":"Lancet Infect Dis"},{"key":"243_CR327","doi-asserted-by":"publisher","unstructured":"Churchyard GJ, Houben R, Fielding K, Fiore-Gartland AL, Esmail H, Grant AD et al. Implications of subclinical tuberculosis for vaccine trial design and global effect. Lancet Microbe. 2024. https:\/\/doi.org\/10.1016\/s2666-5247(24)00127-7.","DOI":"10.1016\/s2666-5247(24)00127-7"},{"issue":"4","key":"243_CR328","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379. https:\/\/doi.org\/10.1038\/nrd.2017.243.","journal-title":"Nat Rev Drug Discov"},{"key":"243_CR329","doi-asserted-by":"publisher","first-page":"100017","DOI":"10.1016\/j.dcit.2024.100017","volume":"2","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Zhang L, Li S, Gao Y, Wang Y, Ma X, et al. S\u20136P exhibits better immunogenicity than S\u20132P at lower doses of COVID-19 mRNA vaccines. Decoding Infect Transm. 2024;2:100017. https:\/\/doi.org\/10.1016\/j.dcit.2024.100017.","journal-title":"Decoding Infect Transm"},{"issue":"Pt A","key":"243_CR330","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijbiomac.2018.08.037","volume":"120","author":"S Khoshnood","year":"2018","unstructured":"Khoshnood S, Heidary M, Haeili M, Drancourt M, Darban-Sarokhalil D, Nasiri MJ, et al. Novel vaccine candidates against Mycobacterium tuberculosis. Int J Biol Macromol. 2018;120(Pt A):180\u20138. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.08.037.","journal-title":"Int J Biol Macromol"},{"key":"243_CR331","doi-asserted-by":"publisher","unstructured":"Ghattas M, Dwivedi G, Lavertu M, Alameh MG. Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines (Basel). 2021;9(12). https:\/\/doi.org\/10.3390\/vaccines9121490.","DOI":"10.3390\/vaccines9121490"},{"key":"243_CR332","doi-asserted-by":"publisher","first-page":"102850","DOI":"10.1016\/j.jddst.2021.102850","volume":"67","author":"K Sarkar","year":"2022","unstructured":"Sarkar K, Kumar M, Jha A, Bharti K, Das M, Mishra B. Nanocarriers for tuberculosis therapy: Design of safe and effective drug delivery strategies to overcome the therapeutic challenges. J Drug Deliv Sci Technol. 2022;67:102850. https:\/\/doi.org\/10.1016\/j.jddst.2021.102850.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"49","key":"243_CR333","doi-asserted-by":"publisher","first-page":"7208","DOI":"10.1016\/j.vaccine.2021.07.091","volume":"39","author":"B Giersing","year":"2021","unstructured":"Giersing B, Shah N, Kristensen D, Amorij JP, Kahn AL, Gandrup-Marino K, et al. Strategies for vaccine-product innovation: creating an enabling environment for product development to uptake in low- and middle-income countries. Vaccine. 2021;39(49):7208\u201319. https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.091.","journal-title":"Vaccine"},{"issue":"1","key":"243_CR334","doi-asserted-by":"publisher","first-page":"21429","DOI":"10.1038\/s41598-022-25827-6","volume":"12","author":"F Kloprogge","year":"2022","unstructured":"Kloprogge F, Ortiz Canseco J, Phee L, Sadouki Z, Kipper K, Witney AA, et al. Emergence of phenotypic and genotypic antimicrobial resistance in Mycobacterium tuberculosis. Sci Rep. 2022;12(1):21429. https:\/\/doi.org\/10.1038\/s41598-022-25827-6.","journal-title":"Sci Rep"},{"issue":"7","key":"243_CR335","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41579-019-0196-3","volume":"17","author":"NQ Balaban","year":"2019","unstructured":"Balaban NQ, Helaine S, Lewis K, Ackermann M, Aldridge B, Andersson DI, et al. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019;17(7):441\u20138. https:\/\/doi.org\/10.1038\/s41579-019-0196-3.","journal-title":"Nat Rev Microbiol"},{"key":"243_CR336","doi-asserted-by":"publisher","unstructured":"Goossens SN, Sampson SL, Van Rie A. Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis. Clin Microbiol Rev. 2020;34(1). https:\/\/doi.org\/10.1128\/cmr.00141-20.","DOI":"10.1128\/cmr.00141-20"},{"issue":"1","key":"243_CR337","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41392-024-01866-5","volume":"9","author":"H Niu","year":"2024","unstructured":"Niu H, Gu J, Zhang Y. Bacterial persisters: molecular mechanisms and therapeutic development. Signal Transduct Target Ther. 2024;9(1):174. https:\/\/doi.org\/10.1038\/s41392-024-01866-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"18","key":"243_CR338","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1016\/j.jmb.2019.02.016","volume":"431","author":"C Vilcheze","year":"2019","unstructured":"Vilcheze C, Jacobs WR Jr. The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis. J Mol Biol. 2019;431(18):3450\u201361. https:\/\/doi.org\/10.1016\/j.jmb.2019.02.016.","journal-title":"J Mol Biol"},{"key":"243_CR339","doi-asserted-by":"publisher","unstructured":"Dechow SJ, Goyal R, Johnson BK, Abramovitch RB. Carbon dioxide regulates Mycobacterium tuberculosis PhoPR signaling and virulence. bioRxiv. 2022. https:\/\/doi.org\/10.1101\/2022.04.12.488064.","DOI":"10.1101\/2022.04.12.488064"},{"key":"243_CR340","doi-asserted-by":"publisher","first-page":"1457012","DOI":"10.3389\/fphar.2024.1457012","volume":"15","author":"A Manaithiya","year":"2024","unstructured":"Manaithiya A, Bhowmik R, Bhattacharya K, Ray R, Shyamal SS, Carta F, et al. A cheminformatics and network pharmacology approach to elucidate the mechanism of action of Mycobacterium tuberculosis \u03b3-carbonic anhydrase inhibitors. Front Pharmacol. 2024;15:1457012. https:\/\/doi.org\/10.3389\/fphar.2024.1457012.","journal-title":"Front Pharmacol"},{"issue":"1","key":"243_CR341","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1080\/14756366.2017.1332056","volume":"32","author":"A Aspatwar","year":"2017","unstructured":"Aspatwar A, Hammaren M, Koskinen S, Luukinen B, Barker H, Carta F, et al. beta-CA-specific inhibitor dithiocarbamate Fc14-584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis. J Enzyme Inhib Med Chem. 2017;32(1):832\u201340. https:\/\/doi.org\/10.1080\/14756366.2017.1332056.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"243_CR342","doi-asserted-by":"publisher","unstructured":"Aspatwar A, Haapanen S, Parkkila S. An Update on the Metabolic Roles of Carbonic Anhydrases in the Model Alga Chlamydomonas reinhardtii. Metabolites. 2018;8(1). https:\/\/doi.org\/10.3390\/metabo8010022.","DOI":"10.3390\/metabo8010022"},{"key":"243_CR343","doi-asserted-by":"publisher","unstructured":"Aspatwar A, Kairys V, Rala S, Parikka M, Bozdag M, Carta F et al. Mycobacterium tuberculosis beta-Carbonic Anhydrases: Novel Targets for Developing Antituberculosis Drugs. Int J Mol Sci. 2019;20(20). https:\/\/doi.org\/10.3390\/ijms20205153.","DOI":"10.3390\/ijms20205153"},{"issue":"24","key":"243_CR344","doi-asserted-by":"publisher","first-page":"13259","DOI":"10.3390\/ijms222413259","volume":"22","author":"MA Ejalonibu","year":"2021","unstructured":"Ejalonibu MA, Ogundare SA, Elrashedy AA, Ejalonibu MA, Lawal MM, Mhlongo NN, et al. Drug discovery for mycobacterium tuberculosis using structure-based computer-aided drug design approach. Int J Mol Sci. 2021;22(24):13259.","journal-title":"Int J Mol Sci"},{"key":"243_CR345","doi-asserted-by":"publisher","unstructured":"Mi J, Wu X, Liang J. The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds. Front Microbiol. 2024;15. https:\/\/doi.org\/10.3389\/fmicb.2024.1380848.","DOI":"10.3389\/fmicb.2024.1380848"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-024-00243-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-024-00243-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-024-00243-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:30:17Z","timestamp":1737545417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-024-00243-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":345,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["243"],"URL":"https:\/\/doi.org\/10.1186\/s43556-024-00243-6","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}